Day one with a consumer EEG headset on your head is an experience. You feel faintly ridiculous. The headband sits across your forehead like a sweatband that wandered into a neuroscience lab. An app on your phone tells you whether your brain is “calm” or “active.” A little graph shows your alpha waves. You sit there, trying to focus, watching yourself try to focus, and wondering if watching yourself try to focus is interfering with the focusing. It probably is.

We ran this experiment across 30 consecutive days with the Muse S Athena, InteraXon’s dual-sensor EEG headband released in March 2025 — the first consumer wearable to combine both EEG (electrical brainwave tracking) and fNIRS (functional near-infrared spectroscopy, which measures blood oxygenation in the prefrontal cortex). The goal was simple and, in retrospect, possibly naive: wear it consistently, do the recommended sessions, track any changes in self-reported focus and productivity, and report back honestly. No control group. No double-blind design. Just one headband, thirty days, and a policy of not lying to ourselves about what we observed. 🧠

How the device actually works — and what it can and can’t measure

The Muse S Athena ($474.99, plus a Muse Premium subscription for full features) gives you four primary EEG channels at positions AF7, AF8, TP9, and TP10, plus fNIRS sensors for prefrontal cortex blood flow tracking. The combination matters: EEG has excellent timing but poor spatial resolution, picking up aggregate electrical chatter across large neural populations. fNIRS adds a slower but more spatially precise hemodynamic signal, tracking which brain regions are working harder. In theory, together they give a more accurate picture of focus states than either alone.

What the app actually shows you:

• A calm score from 0-100 that reflects how much alpha wave activity is present relative to high-frequency beta

• A focus metric derived from the fNIRS blood-flow data in the prefrontal cortex 🔬

• Real-time audio feedback during meditation sessions — birdsong when calm, wind when distracted

• Session-by-session trend data and sleep tracking when worn overnight

What it cannot show you: the specific content of your thoughts, the quality of your attention on a complex task, or anything about deeper brain regions. The electrodes sit on your scalp and forehead. They hear the brain through several layers of skull, scalp, and tissue. A 2026 study published in Scientific Reports comparing consumer EEG devices against a research-grade DSI-24 system found that signal quality degrades substantially in real-world conditions versus controlled labs. The problems: motion artifacts from jaw clenching, blinking, and head movements corrupt the signal; electromagnetic interference from phones, routers, and nearby electronics introduces noise; and the dry electrode contact that makes consumer headsets wearable trades off against the gel-based conductivity that makes clinical EEG precise. 💡

That’s not a reason to dismiss the devices. It is a reason to understand what they’re actually measuring. The Muse is good at detecting states — broadly calm versus broadly activated — and at building awareness of those states over time. It is not a precision instrument for detecting whether you’re genuinely focused on a difficult problem versus just sitting quietly.

What actually happened across 30 days

Week one was the hardest, for reasons that had nothing to do with the device. Habit formation is genuinely difficult. Fitting a 10-20 minute session into a morning before the day accelerates requires either discipline or a very flexible schedule. The headset setup is quick — under two minutes to achieve signal lock — but even two minutes becomes a daily friction point when you’re deciding whether to bother.

By day five, we’d established a consistent pre-work session pattern: 15 minutes of eyes-closed focus training using the Muse app’s neurofeedback mode, where the audio feedback responds in real time to your brainwave state. The audio metaphor is clever. Your brain learns remarkably fast that it controls the sound environment. Within a session, the shift from distracted mental chatter to a quieter baseline becomes almost tangible.

Here is what changed, with precision:

• Session-to-session calm scores improved from a starting average of around 48 to a consistent 65-72 by week three — a meaningful shift in baseline, though we can’t rule out that we simply got better at the specific game the app rewards

• Subjective focus quality during work sessions that followed the morning training felt noticeably better in weeks two and three; by week four, we weren’t sure whether this reflected neural change, the routine of a deliberate morning pause, or confirmation bias from data we were primed to interpret positively 🧬

• Sleep tracking data, captured on nights when we wore the headband overnight, showed what the app described as improved sleep quality scores — though we slept well before the experiment and the baseline wasn’t particularly problematic

• The most concrete observable change: a reduced tendency to immediately reach for a phone during moments of boredom or cognitive load. This might be neurofeedback. It might be the general effect of spending 15 minutes each morning paying close attention to attention itself

What did not change, or changed in ways we couldn’t verify: deep work endurance on genuinely hard cognitive tasks, working memory capacity, reaction time, or any metric we could objectively measure outside the app’s own ecosystem.

The signal quality problem is real, and you should know about it

This is the part that most consumer EEG coverage glosses over, so we’re not going to.

The Scientific Reports paper from Handong Global University, published in February 2026, assessed four consumer EEG devices — including the Muse 2 — against a research-grade system under controlled conditions. The findings were nuanced: consumer devices can produce signal quality comparable to research-grade systems in controlled lab conditions, but real-world deployment introduces substantial degradation. The difference isn’t primarily the device’s inherent capability. It’s the environment. 📈

In a neuroscience lab, you sit still in an electromagnetically shielded room with gel-based electrodes and trained technicians correcting your posture. At your desk, you have a Wi-Fi router three feet away, a phone on Bluetooth, a tendency to clench your jaw when a message arrives, and a posture that shifts every few minutes. All of that corrupts EEG data in ways the app’s signal quality indicator doesn’t fully flag.

The Neurosity Crown comparison is instructive here. The Crown processes EEG signals locally on its own onboard N3 chipset rather than streaming raw data via Bluetooth to a phone — which reduces latency and Bluetooth packet loss, two known signal fidelity problems in phone-dependent systems like Muse. It costs $1,499 with no subscription and offers eight channels versus Muse’s four. For developers who want raw EEG access and API flexibility, it’s a more serious scientific instrument. For someone who wants a structured consumer experience with guided meditation and sleep tracking, the Muse ecosystem is more complete. ⚡

The fundamental limit that neither device overcomes: four or eight channels on a consumer headset can only see a small part of the brain’s electrical activity. A 64-channel research EEG covers the entire scalp. A 256-channel system maps neural activity with the kind of spatial resolution that lets researchers distinguish between attention networks and memory networks in real time. Consumer devices are working with a much rougher signal, and the apps interpret that rough signal through proprietary algorithms that the companies don’t publish for independent review.

This isn’t a conspiracy. It’s a product tradeoff. But it’s worth knowing exactly what you’re measuring before you build a daily habit around the metrics.

What the 30 days actually taught us about attention

Here is the honest finding, separate from the device’s performance: paying daily, structured attention to your attention does something. Whether that something is neural change, behavioral change, or just the effect of a morning routine that enforces a brief pause before the day’s digital noise begins — we genuinely cannot separate these causes with a one-person, uncontrolled experiment. ⚡

What we can say is that the experience is consistent with how consumer EEG researchers at the Centre for Future Generations describe the category: these devices accelerate the growth of self-awareness around cognitive states. They make abstract mental concepts — calm, distraction, focus — legible as data points. That legibility changes behavior somewhat, even when the underlying signal is imperfect.

The TechCrunch framing from Neurable CEO Ramses Alcaide is accurate: these devices don’t read your thoughts. They detect whether your brain is in a focused or distracted state and give you feedback that lets you notice and respond to that state. That’s a narrower capability than the marketing often implies, and it’s a genuinely useful one.

The questions worth asking before you buy:

• Are you looking for a tool to deepen an existing meditation or mindfulness practice? Consumer EEG headsets are probably a useful addition

• Are you hoping to objectively measure cognitive performance on complex tasks? The devices aren’t built for that, and the metrics won’t give you what you want 🔬

• Do you have the consistency to use it five or more times per week for at least eight weeks? Most meaningful changes in consumer neurofeedback users appear after 8-12 weeks of consistent sessions, not after a few days of novelty use

• Are you comfortable with the ambiguity of not knowing exactly how much of your improvement came from the device versus the routine it imposed? Because that ambiguity doesn’t resolve cleanly

As NeurotechMag has covered in previous issues, the consumer EEG market is moving fast enough that these questions will look different in another two years. EEG sensors are already appearing in headphones and earbuds — the HyperX and Neurable collaboration announced at CES 2026 embeds EEG directly into gaming earpads, targeting focus metrics for competitive play. Neurable’s MW75 Neuro headphones hide 12 EEG channels in the earcups and look like regular over-ear headphones. The form factor problem — wearing something that signals “I am measuring my brain” — is being solved by hiding the sensors in things people already wear.

Should you buy one?

Probably, if the price doesn’t hurt, you have realistic expectations, and you’ll actually use it. Mostly definitely not, if you expect it to transform your cognitive performance on its own or you have a history of buying gadgets, using them for a week, and shelving them.

The Muse S Athena at $474.99 is a reasonable entry point for the category — polished app, solid signal for a consumer device, both EEG and fNIRS sensors, good meditation library, and one of the only headsets that doubles as an overnight sleep tracker. The subscription cost (around $130 per year for full features) is a genuine consideration. 💊

The Neurosity Crown at $1,499 makes more sense if you’re a developer, researcher, or someone who wants raw data access and doesn’t need a guided app ecosystem. It’s an 8-channel device with on-device processing, a real SDK, and no ongoing subscription. It demands more from the user but gives more back to users with the technical appetite to use it.

A few practical lessons from 30 days:

• Session consistency matters more than session length. Three 10-minute sessions per week beat one 30-minute session whenever the mood strikes

• Signal quality improves with setup care. Spending an extra 30 seconds adjusting electrode contact reduces artifact noise measurably, even in a dry-electrode consumer device

• The app’s “calm score” is a relative measure, not an absolute one. Track your trend over weeks, not your absolute score on any given day

• Don’t wear it during active cognitive work sessions. The EEG artifacts from typing, moving, and shifting posture corrupt the signal enough that the feedback becomes misleading

Thirty days is enough time to form a habit and start seeing trends. It’s not enough time to be certain those trends reflect genuine neural change versus familiarity with the app’s feedback logic. Honest answer: we’d need six months and a much better experimental design to separate the two.

What we know for certain: attention is trainable, and tools that make attention visible tend to accelerate that training. Whether a $475 headband is the right tool for you depends entirely on how you learn, how consistent you are, and whether you can hold the ambiguity without it driving you toward premature conclusions in either direction.

What would make you willing to try something like this — a lower price, stronger clinical evidence, or the device becoming invisible inside something you already wear?

There is a particular kind of cruelty to anxiety: the harder you try to think your way out of it, the worse it gets. The more you reason with the racing thoughts, the louder they become. It’s your own brain working against you, and no amount of willpower changes the math. This is why, for decades, the standard clinical response has been medication — not because SSRIs and benzodiazepines are perfect, but because they sidestep the problem entirely by adjusting brain chemistry from the outside in.

Neurofeedback therapy proposes a different approach: train the brain to regulate itself. Instead of a pill you take every morning, it’s a learning process, one where your own real-time brain activity becomes the teacher. The idea isn’t new — the field dates back to the 1960s — but the technology behind it, the clinical evidence supporting it, and the consumer devices making it accessible have all shifted considerably in the last few years. If you’ve been looking for an alternative to medication for anxiety, or even just curious about what “brain training” actually means in practice, this is worth understanding. 🧠

What neurofeedback actually does to your brain

Every mental state you experience has a corresponding electrical signature. When you’re anxious, your brain produces excess high-frequency beta waves — the neural equivalent of an engine revving too hard. When you’re calm and alert, alpha waves (8-12 Hz) dominate. When you’re in deep relaxation or creative flow, theta waves (4-8 Hz) emerge. These aren’t metaphors. They’re measurable electrical patterns that EEG sensors pick up from your scalp in real time.

Neurofeedback works by making those invisible patterns visible — and then using that visibility to teach your brain to change them. The basic setup looks like this:

• EEG electrodes attach to your scalp and record your brainwave activity continuously

• Software translates that activity into an audio or visual signal — often music, a video, or a simple game 🎮

• When your brain produces the target pattern (more alpha, less beta, for example), the feedback rewards you: the music plays clearly, the screen brightens, the game progresses

• When you drift away from the target state, the feedback dims or pauses

• Over repeated sessions, your brain learns to produce the target pattern more reliably — a process driven by operant conditioning, the same mechanism that lets you learn anything through reward and repetition

The particular protocol most studied for anxiety is alpha-theta training, developed in the late 1980s by Eugene Peniston originally for combat veterans with PTSD and alcoholism. Alpha-theta training rewards increases in both alpha and theta activity until theta amplitude crosses above alpha, guiding the brain into a deep hypnagogic state — the borderland between waking and sleep where emotional processing becomes unusually accessible. People describe it as profoundly relaxing, sometimes emotionally revelatory. ⚡

What’s appealing about the mechanism is that it’s bidirectional. You’re not suppressing anxiety from the outside in, like a drug. You’re building the brain’s own capacity to self-regulate. The skills, in theory, persist after training ends — unlike medication, which stops working the moment you stop taking it.

What the research actually says (the honest version)

Let’s be straightforward here: the evidence for neurofeedback and anxiety is promising but not settled, and anyone who tells you otherwise is selling something. 🔬

The positive findings are real. A 2025 study published in Frontiers in Public Health tested a Neurofeedback-Assisted Mindfulness Training Program (NAMTP) in a randomized controlled trial running from February 2024 to February 2025, and found it reduced anxiety in young adults. A separate study published in Brain Research in late 2025 assigned 25 participants with moderate or higher anxiety scores on the GAD-7 scale to either real alpha-theta neurofeedback or mock feedback over nine sessions. The real feedback group showed significant anxiety reduction at the end of training; the mock group did not. A 2024 systematic review and meta-analysis in Frontiers in Psychiatry covering neurofeedback for PTSD — which overlaps heavily with anxiety — found consistent symptom reduction across multiple randomized controlled trials.

The critical caveats are also real:

• Most studies have small sample sizes, often 20-30 participants, because the equipment is expensive and the protocols are time-intensive

• Designing a genuine placebo control for neurofeedback is legitimately hard — sham feedback often feels different to participants, which undermines blinding

• A 2025 meta-analysis published in the Journal of Medical Internet Research found that consumer-grade neurofeedback combined with mindfulness was not demonstrably more effective than control conditions in many of the 21 studies it reviewed, and raised the possibility of “neurosuggestion” — essentially placebo effects enhanced by the technology’s authority

• Psychology Today notes plainly that some research shows neurofeedback performs no better than a placebo for certain populations

My reading of this evidence is that neurofeedback probably works for some people and probably doesn’t work for others, and we don’t yet have the tools to reliably predict which group someone falls into before they start. That’s a frustrating conclusion, but it’s an honest one. What I find encouraging is that a November 2025 systematic review in ScienceDirect specifically flagged what the next step needs to be: large-scale, blinded, durability-focused trials with standardized protocols. The research community knows what questions remain open, and they’re asking them. That’s different from a field that’s hiding its weak spots. 📈

The clinical side: what sessions actually look like

For anyone considering professional neurofeedback for anxiety, the practical details matter. A proper clinical program typically starts with a QEEG brain mapping session — a quantitative assessment of your baseline brainwave patterns across multiple frequency bands and electrode sites. This costs between $500 and $3,000 depending on the clinic, and it’s what allows a practitioner to design a protocol actually tailored to your specific brain activity rather than a generic template.

Individual sessions typically run $100 to $300 each. Most anxiety protocols involve 20-40 sessions, often two or three times a week. The math: a full treatment course at a mid-range clinic could run $3,000 to $8,000 not counting the initial mapping. Insurance rarely covers it. That’s a significant barrier and worth naming directly.

What the session itself feels like varies by protocol, but for alpha-theta training, most people describe it as:

• Sitting or lying comfortably with electrodes lightly attached to their scalp

• Listening to music that subtly responds to their brainwave state — becoming clearer during alpha-theta states, fading slightly when beta dominates

• Entering a deeply relaxed, often slightly dreamlike state after 20-30 minutes 💊

• Not “doing” much consciously — the brain learns without deliberate effort

One finding worth paying attention to: Myndlift’s internal data shows that members who completed a dedicated Neuro Coach call were roughly 90% more likely to still be training by session 15 compared to those who didn’t. That’s a striking number, and it suggests that accountability and guidance matter as much as the technology itself. Brain training without a coach is like having a gym membership you never use.

The cost-benefit comparison with medication is genuinely interesting, though not straightforward. Monthly SSRIs for anxiety might run $30-$150 depending on the drug and whether it’s generic. A 30-40 session neurofeedback course at $150 per session is $4,500-$6,000 upfront. But medication requires ongoing cost indefinitely; neurofeedback, if it works, may produce durable results that don’t need constant maintenance. Dr. Andrew Hill’s cost analysis puts the break-even point against ongoing medication and doctor visits at one to three years — though he notes this is a clinical observation and cost-modeling argument, not a head-to-head trial finding. Worth knowing. Not worth overstating.

Does the cost-versus-durability comparison resonate with what you’ve experienced in your own search for anxiety treatments? The tradeoff between upfront investment and ongoing expense is something most people with anxiety have already been navigating for years.

The consumer layer: devices you can try today

The clinical route isn’t the only option anymore. A wave of consumer EEG headsets has brought neurofeedback-style brain training within reach of ordinary budgets, though with meaningful tradeoffs in signal quality and clinical rigor. 🚀

The most established is the Muse S Athena, released in March 2025 by Interaxon — the first consumer wearable to combine both EEG and fNIRS (functional near-infrared spectroscopy) sensors in a single headband. EEG captures electrical brainwave patterns; fNIRS tracks blood oxygenation in the prefrontal cortex. Together, they give a more complete picture of brain state than either alone. Priced around $300-$400, it pairs with the Muse app for meditation neurofeedback and with Myndlift’s clinical-facing platform for more structured training protocols.

Other options worth knowing:

• Sens.ai ($1,450): combines EEG, heart rate variability biofeedback, and photobiomodulation in a single headset; has 16 structured training missions that escalate in difficulty over dozens of sessions

• Mendi ($299): uses fNIRS specifically for prefrontal cortex training; no subscription fees; simpler and more accessible for beginners

• Neurosity Crown ($1,499): 8-channel EEG with an onboard computer and developer API; better suited for productivity hackers and those building their own BCI applications than for anxiety treatment specifically

• FocusCalm ($400 total): developed at Harvard’s Innovation Lab; game-based approach that’s reportedly used by professional athletes in MLB, NFL, and NBA contexts

The honest limitation of consumer devices is what IEEE Pulse flagged in August 2025: there’s a real risk of opportunity cost. If someone invests time and money in a consumer neurofeedback device instead of pursuing a therapy with stronger evidence — CBT, for instance, which has an extremely strong evidence base for anxiety — the device may cause indirect harm even if it causes no direct harm. That’s not a reason to avoid consumer devices. It’s a reason to use them with open eyes, not as a replacement for professional care but as a complement to it or a first step toward understanding your own brain. 🧬

If you do try a consumer device, the realistic timeline from users and small studies suggests: two to four weeks with consistent sessions (three to five per week) before noticing anything at all, eight to twelve weeks before meaningful changes in daily anxiety feel stable, and six months or more for what researchers call deeper neuroplastic changes in baseline stress reactivity.

What to actually do if you want to explore this

Neurofeedback is not magic, and it’s not snake oil. It sits in a genuinely interesting middle ground: real biological mechanism, real clinical evidence in specific contexts, real methodological problems that haven’t been fully resolved, and a consumer market that has outrun the research in some directions.

If you’re considering it, here’s a practical framework:

• Start with your doctor or psychiatrist, not a neurofeedback clinic. Get a full picture of your anxiety — diagnosis, severity, what treatments you’ve already tried — before adding another variable 💡

• Research practitioners carefully. Look for board certification through the Biofeedback Certification International Alliance (BCIA), which requires specific training and ongoing education. The field has enough unqualified providers that credentials genuinely matter

• If cost is a barrier, ask whether any university research programs in your area offer neurofeedback at reduced rates as part of ongoing studies — this is common and underused

• Consumer devices are a reasonable starting point for curiosity but not for treating clinical anxiety on their own. If you try a Muse or Mendi, use it as a tool for self-understanding rather than self-treatment

• Don’t stop medication to try neurofeedback. These are not competing options; they can run concurrently, and dropping a medication without medical supervision is risky

As NeurotechMag has covered in depth, neurotech is no longer limited to lab settings or clinical trials — it’s a consumer reality with real device choices at multiple price points. And as the broader brain-computer interface space has shown, the fastest-moving question isn’t whether these technologies work in principle. It’s how to get the right ones to the right people with the right expectations. ⚡

Neurofeedback for anxiety is squarely in that question. The mechanism is real. The evidence is encouraging in specific populations and weak in others. The devices are accessible. The expertise to use them well is unevenly distributed and genuinely hard to find.

Here’s the question I’ll leave you with: if a treatment works for 40% of people with your condition, has no serious side effects, and doesn’t require you to take a pill every morning for the rest of your life — at what point does the uncertain evidence stop being a reason to wait and start being a reason to try?

Somewhere in Phoenix, Arizona, a man named Noland Arbaugh is browsing the internet using nothing but his mind. He has a small coin-sized implant in his motor cortex, about 1,024 electrodes threaded into his brain like tiny needles of conductive wire, and he spends roughly 10 hours a day controlling a computer cursor with his thoughts. He describes the experience as having his life handed back to him. That’s not a metaphor. It’s a clinical outcome.

Meanwhile, millions of people have never heard the term “brain-computer interface.” That gap — between how fast this technology is actually moving and how little most people know about it — is worth closing. So let’s close it. 🧠

What a brain-computer interface actually does

A brain-computer interface, or BCI, is a system that reads electrical signals from your brain and converts them, in real time, into commands for external devices. That’s the core of it. Your neurons fire, the electrodes pick up the electrical activity, software decodes the pattern, and something happens — a cursor moves, a robotic arm grips, a word appears on screen.

The process has three stages that every BCI system shares:

• Signal acquisition: sensors capture neural activity, either from the scalp (non-invasive) or from electrodes implanted inside or on the surface of the brain (invasive)

• Signal processing: algorithms filter noise and identify the patterns that correspond to intentions or mental states

• Output translation: the decoded signal becomes a command — moving a cursor, typing a letter, controlling a prosthetic limb 🦾

The difference between types of BCIs is mostly about where you put the sensors. Non-invasive EEG headsets sit on your scalp and pick up the faint electrical hum of large groups of neurons firing in unison. They’re safe, affordable, and available to anyone — companies like Emotiv sell consumer headsets that developers use to build everything from attention-tracking apps to meditation feedback tools. The signal quality is lower than invasive systems, though. Think of it like listening to a concert through a wall instead of being in the room.

Invasive BCIs go inside the skull. Neuralink’s N1 implant, the one sitting in Noland Arbaugh’s motor cortex, uses 1,024 electrodes on flexible threads thinner than a human hair. That level of access produces an entirely different quality of signal — crisp, high-resolution, individual neuron-level activity. The tradeoff, obviously, is brain surgery. 🔬

There’s a middle category worth knowing about: electrocorticography (ECoG), where electrode grids sit on the brain’s surface without penetrating the tissue. Companies like Synchron are pursuing a clever variation called the stentrode, a mesh device inserted through a blood vessel into a region near the motor cortex — no open-skull surgery required. It sits in the veins and listens.

Why the medical case is already settled

The original and still most compelling argument for BCIs is medical. The technology restores something that disease or injury took away. That argument is no longer theoretical.

The UC Davis Neuroprosthetics Lab, led by Sergey Stavisky and David Brandman, reported in 2024 that their speech BCI translates brain signals into spoken words with up to 97% accuracy — the most accurate system of its type on record. For patients with ALS or locked-in syndrome, that number is the difference between silence and conversation.

Neuralink’s human trial results tell a similar story. The company’s PRIME Study has implanted devices in patients across the US, Canada, and the UK. What those patients are doing with their implants is remarkable:

• Controlling computer cursors and keyboards by thought alone 💡

• Playing video games and using design software without touching a controller

• Operating a robotic arm to feed themselves — a capability Neuralink calls the CONVOY Study, focused on multi-dimensional physical control

• Browsing the internet, sending messages, and conducting video calls without any physical movement

Nick Wray, the eighth Neuralink recipient and the first with ALS, used his implant to control an assistive robotic arm and feed himself. That’s not a demonstration. That’s lunch.

The broader medical pipeline is just as active. BCIs are in use or clinical testing for post-stroke rehabilitation, Parkinson’s disease, epilepsy, treatment-resistant depression, and visual restoration. Neuralink’s Blindsight project, which received FDA Breakthrough Device designation in September 2024, aims to restore some functional vision to blind individuals whose visual cortex is undamaged. Johns Hopkins researchers have identified neural tissue deformation as a novel signal source for future non-invasive devices. The pace of genuine clinical progress, not hype — actual peer-reviewed progress — is accelerating noticeably. 🚀

The consumer layer you can actually touch today

Here is where things get interesting for people who don’t have neurological conditions and aren’t planning brain surgery anytime soon. Because BCIs are already in your world, you probably just haven’t noticed.

Consumer EEG devices have been around for a decade. The Muse headband measures brainwaves during meditation and gives you audio feedback — real-time neural coaching for your mindfulness practice. The Neurosity Crown tracks cognitive load during work sessions and tells you when your focus is peaking or collapsing. Emotiv makes a range of headsets from $300 earbuds to 32-channel research rigs, all connected to developer APIs so anyone can build BCI-powered applications.

What these devices can actually do — and can’t do — is worth being honest about:

• They detect electrical patterns, not complex thoughts. The headset knows you’re focused; it doesn’t know what you’re focused on

• They’re vulnerable to noise from muscle movements (blinking, clenching your jaw), nearby electronics, and poor electrode contact

• They work well for detecting states — focus, relaxation, stress — rather than decoding specific intentions

• Signal accuracy improves significantly with more electrodes and proper gel contact, which is why research-grade systems cost tens of thousands of dollars

But the consumer space is moving fast. As NeurotechMag has reported, CES 2026 saw LumiMind demonstrate a real-time non-invasive BCI designed not for hospitals but for everyday life. The signal quality gap between consumer and clinical devices is closing, and it’s closing faster than most people realize. 📈

If you’re curious what it actually feels like to experiment with brain data, the devices are available today and cheaper than a decent smartphone. What would you build if you had access to your own real-time neural signals?

The money, the market, and who’s betting big

The investment picture clarifies how seriously the world is taking this. In 2025 alone, disclosed neurotech funding surpassed $1.3 billion across invasive BCIs, non-invasive devices, neuromodulation, and diagnostics. Neuralink has reportedly raised over $650 million to date. Paradromics secured more than $105 million in venture funding plus $18 million from NIH and DARPA. The neurotechnology sector as a whole is projected to grow from around $15-17 billion in 2025 to over $47 billion by 2035.

Who’s driving this?

• Medical device companies betting that BCIs replace or supplement drugs for neurological conditions

• Defense agencies including DARPA, which funds non-surgical neurotechnology research through its Next-Generation Nonsurgical Neurotechnology program

• Tech platforms — Meta explored BCI for AR/VR interfaces before pivoting to non-invasive methods; the interest hasn’t gone away

• China, which has laid out a 5-year government roadmap aiming to become a global BCI leader by 2030

The market projection math alone explains the frenzy. But the smarter observation is that neural data — the raw output of your brain — is a fundamentally different category of information than anything companies have collected before. It can reveal mental health conditions, emotional states, cognitive patterns, even subconscious reactions. Whoever owns that data pipeline owns something extraordinary. 🧬

This is why the competitive moat for neurotech companies isn’t branding or distribution. As NeurotechMag has explored in depth, it’s the combination of proprietary neural datasets, deep regulatory expertise, and cross-disciplinary IP — things that take years to build and can’t be copied overnight.

The part that should make you think carefully

The same properties that make neural data medically valuable make it potentially dangerous in the wrong hands. This isn’t paranoia. It’s what US Senators wrote to the FTC in April 2025, urging action to protect Americans’ neural data from “potential exploitation or sale, as brain-computer interface technologies rapidly advance.” Their letter noted that, unlike other personal data, neural data can reveal mental health conditions, emotional states, and cognitive patterns even when anonymized.

That’s a genuinely unsettling sentence. Anonymized data is usually considered safe — that’s the whole point of anonymization. Neural data breaks that assumption.

The regulatory picture is currently inadequate in a way that should concern anyone following this space:

• The GDPR does not clearly cover neural data, meaning existing European privacy law has significant gaps

• The FDA classifies most implantable BCIs as Class III devices with rigorous safety review, but current guidance lacks detailed provisions for the ethical handling of neural data

• A 2024 review of consumer neurotechnology companies found that nearly every company reviewed appeared to have access to user neural data with “no meaningful limitations” on that access

• Chile has constitutional protection for mental integrity; California classifies neural data as sensitive personal information — but these are outliers, not the norm ⚡

The darker scenarios researchers worry about include insurers using neural risk factors to deny coverage, employers screening for cognitive traits during hiring, and governments surveilling dissent through brain activity. These are not science fiction scenarios. They are the logical extension of applying existing bad-faith data practices to a far more intimate category of information.

There is also the question of what happens when the technology works too well. If a future BCI can decode your internal monologue — not just attempted speech, but your actual private thoughts — at what point does mental privacy cease to exist? Researchers at UC Davis have already decoded speech attempts at 97% accuracy. The path from there to inner speech isn’t infinite.

None of this means the technology should stop. The medical case for BCIs is compelling enough that halting research would cause its own enormous harm. But it does mean that the people building these systems, the regulators overseeing them, and the users adopting them need to think harder and faster than they currently are.

Where this is actually going

The ten-year trajectory is clearer than it’s been at any point in BCI history. Non-invasive devices will become more accurate as AI signal processing improves. Implants will become safer and longer-lasting as materials science catches up. The surgical bottleneck — there aren’t enough trained neurosurgeons to scale implant procedures — will ease as Neuralink and others develop robotic surgical systems. Neuralink announced in May 2026 that its surgical robot can now place electrode threads into virtually any region of the human brain, moving from motor restoration into Parkinson’s, epilepsy, and depression territory. Earlier surgical robot iterations that cost $10-20 million can now be manufactured for approximately $500,000. That’s a different cost curve.

The near-term reality, though, is probably less dramatic than the headlines suggest and more meaningful than the skeptics admit. Within the next decade, BCIs will almost certainly:

• Restore communication and physical control to a meaningful number of people with paralysis, ALS, and stroke damage 🔬

• Enable non-invasive attention and cognitive state monitoring in productivity and wellness applications

• Begin integration into AR/VR interfaces as a more intuitive control layer than hands or voice

• Generate enormous regulatory battles over data ownership, access, and privacy

• Split into a medical-grade track with serious oversight and a consumer track that remains largely unregulated

What they probably won’t do within that window is deliver the seamless human-AI symbiosis that the most enthusiastic boosters promise. Decoding complex intentions from messy neural signals is genuinely hard, individual brains vary enormously, and the gap between “detecting focus states” and “reading thoughts” is still vast.

But here is what strikes me most when I look at this field honestly: we are already past the point of asking whether BCIs work. We are at the point of asking who gets them, who controls the data, and what we do when the technology outpaces our ability to govern it. Those are not engineering questions. They are political and ethical ones, and they need more attention than they’re currently getting.

What would change for you personally if a non-invasive BCI could tell you — reliably, in real time — whether you were actually focused or just performing focus? I’d genuinely like to know.

Nobody in the brain implant business wants to talk about this. The conference presentations focus on neural decoding, surgical robotics, and the extraordinary things paralyzed patients can do when a chip talks directly to their motor cortex. The press releases announce funding rounds. The clinical coordinators explain informed consent. But somewhere in the fine print of every patient agreement, in the risk disclosures nobody fully reads, there’s a question that the whole field is quietly hoping not to answer: what happens to the person wearing this thing if the company building it runs out of money?

It’s not a hypothetical. It has already happened, more than once, to devices that sit in people’s skulls and retinas and spinal cords right now. The bodies are in the ground — or more accurately, the defunct devices are in people’s bodies — and the regulatory framework still hasn’t caught up. As companies like Neuralink talk about high-volume production and thousands of annual implants, and as smaller startups race to reach patients with devices for depression, paralysis, and epilepsy, the failure scenario is moving from an edge case to a structural probability. Some of these companies will go under. That’s not cynicism. That’s statistics.

I think this is the most underreported risk in neurotech, and it’s not even close.

The cautionary tales already on the books

The history here is short but consequential. Nuvectra, a manufacturer of a spinal cord stimulator for chronic pain, filed for bankruptcy in 2019. That same year, Second Sight, an artificial-vision company, began hemorrhaging money and advised its implantees that it was stopping production of retinal implants. In early 2020, the CEO and director of R&D exited suddenly, most employees were laid off, and the company started auctioning its physical assets, leaving approximately 350 people fitted with a Second Sight implant to wonder what was happening.

The Second Sight case is the one that should keep every neurotech investor and regulator up at night. After Second Sight abandoned the Argus II retinal prosthesis, users not only lost their regained vision but were left with an obsolete device implanted in their bodies, forced to decide between the risks of leaving it in or the risk and cost of having it removed. One patient, Terry Byland, who was the only person ever implanted with Second Sight devices in both eyes, found out secondhand through press coverage that the company was collapsing. Nobody called him. The device that had given him back his ability to see the world was now a permanent, inert foreign object in his face, with no technical support, no replacement parts, and no one left who knew its proprietary components well enough to help a surgeon safely remove it.

And the cruel irony: despite its treatment of those users, Second Sight subsequently received a new round of NIH funding to support research and testing of a different neural prosthesis.

The pattern doesn’t stop with commercial bankruptcy. Sometimes the killer is simply funding running out. Ian Burkhart, who in 2014 became the first paralyzed person in history to regain hand movement using a brain-computer interface, used his device through the Ohio State University trial for seven and a half years. After funding for the trial ran out, he had to have the device removed in 2021. “It definitely was a sad time,” Burkhart said. “I was able to restore that function, and then lose it once again. That was really tough.” 💔

He’s now the founder of the BCI Pioneers Coalition, an advocacy group pushing for the industry to get its act together on patient protections. His core proposal is simple and has apparently been impossible to implement: companies should be required to set aside funds covering ongoing device maintenance and removal on the patient’s timeline, not the company’s.

The abandonment risk looks like this in practice:

• Commercial bankruptcy: company folds, no successor, device becomes an unsupported orphan with no parts supply, no technical support, and documentation locked inside a liquidated IP portfolio

• Strategic pivot: company stops supporting an older device to focus resources on a newer product, as Second Sight did when it abandoned the Argus II to chase the Orion

• Trial funding ends: publicly funded research concludes, patients lose access regardless of whether the device is still working

• NIH or government funding cuts: federal support evaporates mid-trial, as hundreds of participants discovered in 2025 when NIH funding cuts disrupted experimental treatments for depression and quadriplegia

Explantation: the option that isn’t really an option

When the company disappears, patients face a choice that the medical community frames as binary but is really just two versions of bad.

Option one: leave the device in. A defunct implant isn’t necessarily dangerous on its own. When companies go under, the implants they created are typically left in place — surgery to remove them is often too expensive, too risky, or simply deemed unnecessary. An inert electrode array sitting in your motor cortex isn’t going to kill you. But it might complicate an MRI, interfere with other procedures, degrade over time in unpredictable ways, and — in the case of devices that were actually working — leave you with the permanent psychological weight of carrying something that used to restore a function you’ve now lost again. A patient named Carol Seeger, who treated her severe depression with an experimental deep brain stimulation device, described what happened when her device’s batteries failed and insurance refused to cover repairs: she sank back into dangerous darkness and worried for her life. “If this turns off, I get sick again. Like, I’m not cured. This is a treatment that absolutely works, but only as long as I’ve got a working device.”

Option two: have it removed. Replacing an obsolete implant like Nuvectra’s spinal cord stimulator requires surgery that takes weeks to recover from and costs around $40,000. And that assumes a replacement device is available. For brain implants specifically, the removal risk is higher and the costs steeper, because you’re asking a surgeon to undo something that required extreme precision to install, using documentation that may no longer exist if the company’s IP has been liquidated. Insurance programs generally have no legal obligation to cover device removal unless it is deemed medically necessary for physical reasons, such as infection or device failure. Removal for psychological distress or strong personal preference is not typically considered medically necessary, meaning patients may have to cover the cost themselves — approximately $11,500 for DBS device explantation in some estimates.

Frederic Gilbert, an associate professor at the University of Tasmania who specializes in neurotech ethics, has made the point that removing a device can be tantamount to withdrawing treatment, because these devices can profoundly affect a patient’s identity — and the distress caused by removal may be directly proportional to how effective the device was. That’s an observation that hasn’t yet worked its way into how companies think about their obligations, or how regulators frame their requirements. 🧠

The situations patients can find themselves in:

• Device still physically functional but software unsupported and unable to receive updates

• Device hardware failing with no replacement parts available

• Technical documentation locked inside a company’s proprietary system, inaccessible to any surgeon or support team

• Insurance refusing to cover removal because the indication isn’t “medically necessary”

• No identifiable legal entity to hold accountable for the abandonment

The regulatory gap that shouldn’t exist

Here’s what’s genuinely maddening about this situation: there is no federal requirement in the United States that forces a medical device company to designate a successor entity, fund a maintenance reserve, or guarantee long-term support for patients carrying their devices. The FDA’s post-market surveillance requirements for Class III devices focus on safety reporting and performance monitoring. They do not require companies to plan for their own failure.

The FDA does require device tracking for certain high-risk implantables, meaning manufacturers must know who has their device so they can issue recalls or field safety notices quickly. That’s useful for hardware defects. It is completely silent on what happens when the company stops existing. As researchers writing in STAT News argued, regulators should require that companies developing technologies that become integrated into patients’ bodies and brains have a duty of care, be liable for negligence or malpractice like medical professionals, and designate a successor in the event of failure or bankruptcy so users are ensured indefinite support. That proposal has been on the table since 2022. Nothing has moved on it. ⚡

One meaningful partial solution would be open-sourcing device documentation. With open-source information about proprietary medical devices, a third party would be able to access what it needs to take on the complex responsibilities of supporting implant users in the event of business failure. Burkhart himself has pushed for industry-wide component standards, noting that if batteries were interoperable across devices the way phone chargers eventually became, maintaining a device after the original company folds would be dramatically more feasible.

The advocacy community is trying to move the needle. The BCI Pioneers Coalition has been pushing companies and regulators to hear directly from trial participants, and Burkhart’s recognition on MIT Technology Review’s 2025 Innovators Under 35 list has given the issue some profile. But patient advocacy has yet to translate into enforceable regulatory requirements. 🔬

Meanwhile, the scale problem is growing in one direction only. Neuralink has publicly stated plans to move toward high-volume production, with thousands of implants annually as the near-term target and a long-term vision of tens of millions. The current neurotech startup field attracted approximately $2.1 billion in venture investment in 2025, a 62% increase from 2023 — a funding surge that will produce not just successful companies, but also, statistically, a significant number of failed ones. Some of those companies will have devices in people’s heads when they go under.

What a responsible framework would actually require

The structural fix here isn’t complicated in concept. It’s just politically and commercially inconvenient, which is why it hasn’t happened.

A responsible framework for long-term device support would include: 💡

• Mandatory succession planning: as a condition of FDA approval for any long-term implantable neural device, companies must designate a named successor entity or establish a maintenance trust before the first device is implanted

• Escrow requirements: companies must fund a maintenance reserve proportional to their implanted patient population, calculated to cover device support and explantation costs for the expected device lifetime

• Open documentation requirements: technical documentation sufficient for a qualified third party to maintain or explant a device must be held in escrow and released automatically if the company becomes insolvent

• Insurance coverage mandates: the “not medically necessary” exclusion cannot apply to explantation when the necessity arises from corporate abandonment rather than clinical indications

There’s a broader question about whether venture-backed startups are the right legal structures to be putting permanent devices in people’s brains at all — not because the science is wrong, but because the incentive structures don’t line up well with indefinite patient obligations. A venture fund expecting a 10-year return horizon and an implant patient expecting lifetime support are operating on completely incompatible timelines.

The NeurotechMag piece on how neurotech is quietly replacing antidepressants for some patients makes the case that this space is genuinely moving toward mainstream adoption — which makes the governance question not more abstract but more urgent. The same thing is true across the wider equity and access questions that come with brain implants scaling up, which we’ve covered separately on how mainstream brain implants could widen the inequality gap.

The question worth asking out loud: if a company can’t credibly guarantee it will support the devices it puts in people’s heads for the lifetime of those people, should it be permitted to implant them in the first place? That might sound radical. But the alternative — the status quo where Second Sight patients discover their vision is going dark because a startup pivoted — is not a hypothetical risk scenario. It already happened. It will happen again. The only question is whether we build the infrastructure to handle it before the next time, or after. 🚀

There’s a version of the brain implant future that reads like a utopian brochure. Depression? Treated with a blueberry-sized chip in your skull. Paralysis? Bypassed entirely with a thought-to-cursor interface. Parkinson’s tremors? Quieted by a pacemaker wired to your basal ganglia. The technology is real, the clinical trials are enrolling, and the results so far are, in a few select cases, remarkable.

There’s another version of that future, though. One where the people who get access to those tools are exactly the people who already had better healthcare, more job security, higher salaries, and better educational outcomes. One where the gap between the cognitively augmented and the cognitively unaugmented stops being metaphorical and becomes literal, permanent, and measurable in electrode counts. That version is also on the table. And compared to the utopian one, it gets almost no attention.

I think about this a lot. The neurotech field is genuinely producing tools that could help millions of people who have failed every conventional treatment. That’s not hype — it’s verifiable and documented. But the same field is operating inside healthcare and economic systems that have a long, unambiguous track record of translating “available” into “available to some.” The question isn’t whether brain implant technology will arrive. It’s who gets to live inside it.

The price tag problem is already showing up

Start with the numbers, because they’re grounding.

Elon Musk has projected that high-volume Neuralink production could eventually bring device costs to $2,000-$3,000, while current early commercial procedures are estimated at around $10,500 in parts and labor — a figure that swells to approximately $40,000-$50,000 when insurer overhead is included. That’s the optimistic trajectory, and it assumes the kind of manufacturing scale that doesn’t yet exist.

Deep brain stimulation, the older and better-proven form of brain implant, has a clearer cost picture — and it’s not comfortable reading. Medicare does cover DBS for approved indications like Parkinson’s disease and essential tremor, provided patients meet strict eligibility criteria, including demonstrated limitations in daily activities and the ability to participate in postsurgical evaluations. But DBS for treatment-resistant depression isn’t yet approved by the FDA for commercial use, meaning insurers have no obligation to cover it. Currently, no specific insurance plans cover experimental neurostimulation technology, and future coverage will depend on FDA approval and demonstrated efficacy.

The pattern here is familiar to anyone who has watched a new medical technology enter the US healthcare system: 💡

• Clinical trials cover costs for enrolled participants — but trial slots are scarce, selective, and geographically concentrated at academic medical centers

• Early commercial access lands at premium pricing, mostly reachable through private insurance or out-of-pocket spending

• Broader insurance coverage follows, sometimes by years or decades, and is often incomplete even then

• Medicaid and lower-income populations typically arrive last, if at all

The BCI implant market was valued at roughly $351 million in 2025, with projections to reach $1.18 billion by 2035. That’s not a public health infrastructure story. That’s a premium medtech story, with premium medtech distribution patterns. And for every year a therapy remains outside standard insurance coverage, it accumulates a waiting list sorted by wealth.

China is, interestingly, trying something different. In March 2025, China’s National Medical Insurance Administration created a new insurance category specifically for BCI technology, directly addressing cost as one of the biggest barriers to adoption. Whether that coverage is substantive or nominal, it’s a structural choice the United States hasn’t made and shows no signs of making soon. 🔬

When “available” and “accessible” diverge

The access problem isn’t just about price. It’s about the entire infrastructure that connects a person to an experimental or newly approved medical device.

Consider geography. The TRANSCEND trial — Abbott’s pivotal study of deep brain stimulation for treatment-resistant depression — has 25 participating sites nationwide, including Mount Sinai in New York and Emory University in Atlanta. Those are world-class institutions. They are also in major metropolitan areas where neurological expertise, follow-up care, and the broader medical scaffolding those surgeries require already exist. Research has found that access to deep brain stimulation has historically marginalized remote communities, with recommendations emerging for telehealth-supported care as a partial solution. Partial is the operative word.

Then there’s the skill gap. Brain implant surgery requires neurosurgeons with highly specific training. The United States has roughly 3,000 neurosurgeons total, and the subset trained in stereotactic implant procedures is smaller still. Scaling up to even tens of thousands of patients annually, let alone hundreds of thousands, requires either a dramatic expansion of surgical training or the kind of robotic automation that Neuralink is building toward. Neither is fast. Neither is cheap. And in the interim, patients in rural areas, underserved communities, and regions without major academic medical centers will face access barriers that have nothing to do with their ability to pay. 📈

What does this look like in practice? A patient with severe treatment-resistant depression in rural Mississippi may have:

• No neurologist within 100 miles, let alone a neurosurgeon with DBS experience

• Medicaid coverage that won’t reach experimental devices for years after FDA approval

• No trial eligibility because trial sites don’t exist near them

• No advocacy infrastructure to navigate a complex experimental device process

• No time off work for the multiple surgical and follow-up appointments an implant requires

Compare that to a patient in Boston or San Francisco with private insurance, proximity to a major academic medical center, and access to a knowledgeable psychiatrist who’s tracking emerging treatments. These two patients may have identical diagnoses, identical unmet needs, and radically different outcomes — not because of neuroscience, but because of zip codes and paychecks. That’s not a hypothetical future problem. It’s a current-day structural pattern that brain implants will slot directly into. 🧠

The enhancement problem: when treatment becomes advantage

So far, I’ve focused on the therapeutic side — devices designed to restore function to people who have lost it or never had it. That’s where the strongest moral case for brain implants lives, and that’s where the current clinical trials are focused.

But here’s the problem: the line between restoration and enhancement is not clean, and it gets blurrier as the technology matures. A frequently voiced concern in academic neuroethics is that neurotechnologies might be used to cognitively enhance only those who can afford them, unfairly increasing the divide in society. Elon Musk has been explicit that Neuralink’s long-term goal is not just medical restoration — it’s enhancement of healthy individuals. That’s a different conversation entirely.

And the workplace is already moving toward neurotech without waiting for implants. Brain-monitoring neurotechnology is already used in mining, finance, and other industries to measure brain waves and infer cognitive states, and the UK’s Information Commissioner’s Office predicts it will be common in workplaces by the end of the decade. The people whose employers are investing in that technology are not the same people whose employers are cutting benefits. The cognitive advantages of neurotech — enhanced focus, better stress management, faster learning through neurostimulation — will initially be available to workers at companies that can afford them.

That creates a particularly uncomfortable scenario where:

• Knowledge workers at well-resourced companies get non-invasive neuroenhancement tools as workplace perks

• Blue-collar workers get neuro-monitoring devices — their cognition tracked for fatigue and compliance, not enhanced for performance

• The resulting productivity data flows upward to employers, not sideways to workers who generated it

• Early adopters of enhancement implants gain cognitive advantages in hiring, promotion, and competitive performance that compound over careers

Neurodevice data obtained from workers could theoretically serve employers for purposes like promotion, hiring, or dismissal, something researchers at the University of Zurich have flagged specifically as a risk. The class dynamics of that scenario are not subtle. 💊

What the regulatory picture actually looks like

On November 12, 2025, UNESCO adopted its Recommendation on the Ethics of Neurotechnology — the first attempt at a global legal framework for the ethical development and use of neurotechnology, covering the entire lifecycle from design to disposal. The framework emphasizes human dignity, mental privacy, informed consent, and — importantly — equity. The UNESCO Recommendation explicitly states that neurotechnology should be used to reduce global health inequalities and improve health particularly in resource-limited settings.

That sounds good. The problem is that the Recommendation is non-binding. It carries no enforcement mechanism. A company that violates its principles faces no penalty. Its value is entirely aspirational — a normative framework hoping to be adopted by individual nations through their own legislative processes, which is a slow and inconsistent path.

The more enforceable action is happening at the state level in the United States, focused narrowly on neural data privacy. Colorado, California, and Montana have enacted laws treating neural data as sensitive personal information with specific protections. Colorado recognizes neural data as private property, granting residents the right to access and delete their neural data held by technology companies, and to prohibit its use for marketing purposes. That’s meaningful. But data privacy and access equity are different problems, and only one is getting serious legislative attention right now.

Chile remains the most notable national example. Chile became the first country in the world to amend its constitution to protect brain rights, including mental privacy, free will, and non-discrimination in citizens’ access to neurotechnology, with a goal of giving personal brain data the same status as an organ — not for sale, not for trafficking, not for manipulation. That’s a significantly more ambitious legal framework than anything the United States or EU has passed. But Chile’s neurotech industry is also not where the dominant BCI companies are operating. 🌍

What the global policy picture actually shows:

• The most ambitious equity frameworks are nonbinding international guidance documents

• The most enforceable regulations cover data privacy, not access or pricing

• The nations with the most neurotech commercial activity (US, Europe, China) are taking different and incompatible approaches

• The countries with the least existing healthcare infrastructure have essentially no neurotech policy at all

What a different path might look like

I want to be honest that this isn’t a solved problem with obvious policy answers. The history of medical technology does include cases where costs came down and access broadened — HIV antivirals, cochlear implants, and certain cancer therapies all eventually reached populations that couldn’t have afforded them at launch. The optimists point to this history and argue that brain implants will follow the same curve. They might be right.

But those historical examples also took decades, often required significant advocacy and political pressure, and still left major access gaps globally. And unlike antivirals, brain implants require surgical infrastructure and ongoing clinical management that pills do not. The comparison may not hold as well as the optimists assume.

The NeurotechMag piece How Neurotech Is Quietly Replacing Antidepressants for Some Patients maps how the non-invasive end of the spectrum — consumer headsets and wearables — is diffusing faster than implants. That’s genuinely encouraging. But non-invasive devices and invasive implants don’t cover the same ground. For the severest cases of treatment-resistant depression, paralysis, or Parkinson’s, only implants get close enough to make the difference.

Specific interventions that researchers and bioethicists have proposed include: ⚡

• Mandatory access planning as part of FDA approval pathways for high-cost neural devices, requiring manufacturers to submit reimbursement strategies alongside efficacy data

• Public funding for trial site expansion to underserved regions, not just major academic medical centers

• Neural data as a public good framework, in which the data generated by implanted devices cannot be commodified or used as a commercial asset without explicit benefit-sharing with patients

• International technology transfer mechanisms modeled on existing vaccine access programs, so that BCI technology developed in wealthy nations doesn’t simply bypass lower-income countries entirely

None of this is politically easy. Some of it is politically close to impossible in the current US environment. And the companies building these devices — funded by venture capital with specific return expectations — are not structurally aligned with equity goals unless regulatory frameworks create that alignment.

UNESCO itself has noted that if access to advanced neurotechnology is limited to the wealthy, it could further increase the gap between this social group and others at the international, national, or local level, and potentially lead to social tensions and conflict. That’s a careful way of saying something less careful: a world where some people’s brains are literally more capable than others because of money is a world with a new and unusually deep axis of inequality. Not metaphorically. Structurally.

So here’s the question worth sitting with: if we accept that brain implants will help some people dramatically, and we also accept that unmanaged markets will distribute them unequally, what exactly are we willing to do about it — and when? Because right now, the technology is moving faster than the policy, and the window for getting the structural choices right is open but not indefinitely.

The psychiatrist’s standard playbook for severe depression looks roughly like this: try one antidepressant, wait six weeks, try another, adjust the dose, add a second drug, wait some more, wonder if anything is working. Somewhere between 30% and 40% of everyone treated with antidepressants never gets adequate relief. That’s not a rounding error. That’s tens of millions of people stuck in a loop that medicine hasn’t broken in decades.

What if the answer isn’t a pill at all? What if it’s a blueberry-sized gadget sitting quietly in the bone above your brain, sending electrical pulses to the exact network that’s gone dark? That’s not science fiction anymore. It’s the premise of at least two active clinical trials in the United States right now, with a third just receiving FDA clearance to begin. The neurotech field is betting, seriously and with significant institutional money, that treatment-resistant depression (TRD) is not a psychiatric puzzle but a circuit problem, and circuit problems can be fixed with the right hardware.

I think we’re at an inflection point. Not the breathless, “cure is imminent” kind, but the kind where the evidence is finally mature enough to run proper randomized trials, and the engineering has shrunk enough to make implants feel less like sci-fi horror and more like routine cardiology. Here’s where things actually stand.

The scale of the problem nobody talks about enough

Depression is the leading cause of disability worldwide, according to the World Health Organization, but the version that makes headlines is rarely the most severe form. Treatment-resistant depression, defined as failing to improve after at least two separate courses of antidepressants, affects approximately 3 million Americans each year, and that number almost certainly undercounts the true burden.

The economics are brutal. The total annual healthcare burden of TRD in the United States is estimated at $43.8 billion. And the human cost is harder to quantify. Data from the UK’s National Health Service suggests that close to half of all people with major depressive disorder may develop treatment-resistant depression, a finding that, if it holds up, would be a major reframing of how common TRD really is. Most people think of it as a rare edge case. It isn’t.

The failure modes of standard treatment are worth knowing:

• SSRIs and SNRIs work well for many, but roughly one in three patients gets inadequate relief even at appropriate doses and duration

• Up to two thirds of patients will not respond to the first antidepressant prescribed, which means the second, third, and fourth tries are grinding through diminishing returns

• By the fourth failed medication trial, as many as 83% of patients relapse — a statistic that should make anyone uncomfortable

• The condition carries elevated rates of anxiety disorders, self-harm, and suicidality compared with non-resistant depression

This is the patient population that neurostimulation researchers have been quietly targeting for years. The logic is straightforward: advances in neuroscience have made it clear that major depressive disorder involves identifiable structural and functional changes in the brain, just like Parkinson’s disease does. And Parkinson’s, notably, is already treated with implanted electrical devices in tens of thousands of patients. Why should depression be any different? 🔬

The two approaches making the most noise right now

The two big strategies in clinical development are deep brain stimulation (DBS) and a newer category of minimally invasive over-brain stimulation, and they work quite differently.

DBS is the older, better-understood approach. It works like a pacemaker for the brain: a surgeon implants thin wire electrodes deep into a targeted brain structure, connects them to a pulse generator under the skin in the chest, and the device delivers continuous or adjustable electrical impulses to modulate abnormal activity. Previous open-label studies demonstrated at least a 50% sustained improvement in depression symptoms for three out of four patients over a period of two to eight years, which is, frankly, a remarkable result for a condition that had exhausted every other option. The problem is that those were open-label studies, meaning patients and doctors both knew treatment was occurring, which always inflates outcomes.

That’s why the TRANSCEND trial, run by medical device giant Abbott, matters so much. The TRANSCEND (Treatment ResistAnt DepressioN Subcallosal CingulatE Network DBS) study is a double-blinded, randomized, multi-site trial investigating Abbott’s DBS system specifically in people who have failed at least four antidepressant treatments. Half the participants won’t receive any active stimulation for the first 12 months — a sham-control design that eliminates placebo effects. Emory University joined as one of 25 participating sites nationwide, with enrollment actively ongoing. Mount Sinai was the first site to perform the DBS implantation procedure under the trial in March 2025, following years of preclinical and regulatory groundwork.

The Motif Neurotech approach is structurally different and arguably more interesting from an engineering standpoint. Their device, called DOT (Digitally Programmable Over-brain Therapeutic), is roughly the size of a blueberry. It sits in the bone above the brain rather than inside it, doesn’t touch brain tissue directly, and is implanted in a 20-minute outpatient procedure. It’s wirelessly powered. You walk in, you walk out, and you go home with something that can deliver brain stimulation daily without ever needing a clinic visit. In late April 2026, the FDA cleared Motif’s RESONATE trial — the company’s first-in-human study, which will initially enroll around 10 participants over 12 months.

The key distinctions between the two approaches: 🧠

• DBS targets deep brain structures (specifically the subcallosal cingulate cortex), requires more invasive surgery, delivers stronger stimulation, and has a longer evidence base

• DOT/Motif sits above the brain, targets the same cortical network as transcranial magnetic stimulation (TMS), is minimally invasive, and is designed for completely unsupervised at-home use

• Both are aimed squarely at the roughly 3 million Americans for whom nothing else has worked

• Both carry FDA Breakthrough Device designations, meaning the agency agrees the unmet need is severe enough to warrant accelerated review

Jacob Robinson, Motif’s CEO, has framed the long-term vision memorably: the goal is that this technology would be the “mental health equivalent of a continuous glucose monitor for diabetes.” That’s an ambitious analogy. But given where the science is heading, it might not be as far-fetched as it sounds. 💡

Closed-loop systems: the real paradigm shift

Here’s the part of this story that I find genuinely fascinating, and that most mainstream coverage completely misses. Both current trials deliver what’s called open-loop stimulation — the device runs on a fixed schedule, regardless of the patient’s actual brain state at any given moment. That’s like dosing insulin at fixed times regardless of blood sugar levels. It works, but it’s blunt.

The next generation is closed-loop, or adaptive, neurostimulation. Rather than continuous stimulation, closed-loop therapy aims to deliver short, intermittent stimulation only when the patient’s brain signals indicate they are in a depressive state, using neural biomarkers detected in real time to trigger the device. Think of it as a thermostat for your mood circuitry. When the relevant biomarker signal drops, the implant fires. When things normalize, it stops.

A landmark proof-of-concept published in Nature Medicine showed that this personalized biomarker-driven approach can produce rapid and sustained improvement in a patient with severe depression. Early results from an ongoing closed-loop DBS trial suggest that the total stimulation time needed to achieve a clinical effect may be under two hours a day — a stark contrast to the 24/7 continuous stimulation used in traditional DBS. That’s a huge deal, because it may reduce risks like hypomania (an unintended mood elevation that’s been a known side effect of DBS) and prevent the brain from adapting and becoming habituated to the signal.

This approach got a commercial foothold in a related indication: in February 2025, the FDA approved Medtronic’s Percept RC neurostimulator with BrainSense, the world’s first commercially available adaptive DBS system — though initially cleared for Parkinson’s disease, not depression. The infrastructure, the sensing, the algorithmic approach — it’s all being developed. Translating it to psychiatric conditions is the next logical step. 🔬

But there’s a catch. Biomarkers for depressive states can differ significantly across individuals due to neurocircuit heterogeneity, which means a “one-size-fits-all” biomarker almost certainly won’t work. Truly personalized closed-loop therapy requires mapping each patient’s unique neural activity patterns before treatment can be calibrated. That’s workable, but it adds complexity, time, and cost to an already resource-intensive intervention.

What the trials can and can’t tell us yet

Let’s be honest about what we don’t know, because the gap between promising trial results and an approved therapy is wider than most coverage implies.

A UK-China study of DBS for treatment-resistant depression reported clinical improvements in roughly half of participants in an open-label trial, and researchers identified neural activity signatures that predicted individual patient response — which is genuinely useful for targeting future treatment. But a double-blind randomized controlled trial from the same group is still pending publication. Results from Abbott’s TRANSCEND trial aren’t expected for years. Motif’s RESONATE study is just beginning. This is early. Very early.

The ethical questions are also non-trivial and deserve more airtime than they usually get. A major scoping review of the past decade’s neuroethical literature found that concepts of changes in patient identity and personality after deep brain stimulation were extensively discussed, with DBS being considered both the riskiest and highest-efficacy option. Mood, personality, and sense of self are not incidental byproducts of a functioning brain — they are the brain. Stimulating specific circuits that regulate affect raises real questions about what, exactly, is being altered.

Issues of data privacy, user autonomy, equitable access, and long-term safety remain unresolved in the BCI space broadly, with researchers noting the risk that commercial pressures could overshadow patient welfare. That risk is particularly acute in psychiatry, where patients may be in severe distress, may have limited capacity to evaluate experimental options, and may feel that an implant is their last resort. Desperation is not the same as informed consent.

There’s also the access problem. DBS surgery costs tens of thousands of dollars. Even if Abbott’s TRANSCEND trial proves efficacy, the path from “it works in a clinical trial” to “your insurance covers it” in the United States is long and ugly. Motif’s minimally invasive design is explicitly aimed at reducing that barrier — a 20-minute outpatient procedure is orders of magnitude cheaper than open brain surgery — but we’re still talking about an implantable device, not a $40 prescription. 💊

Questions worth sitting with:

• Who gets access first, and how do we prevent neuro-implant therapy from becoming another luxury treatment available only to the wealthy?

• What happens if a patient’s personality changes in ways they — or their family — didn’t anticipate?

• When a device is removed or stops working, what are the psychological consequences?

• If a closed-loop device is reading your neural biomarkers continuously, who owns that data?

What comes next, and why this moment matters

The honest answer to the headline question — can a brain implant treat depression? — is probably yes, for some patients, under specific conditions we don’t yet fully understand. That’s less satisfying than a binary answer, but it’s more accurate.

What we do know is that the neuromodulation approach to depression has cleared a significant credibility hurdle. The FDA’s Breakthrough Device designations for both Abbott’s DBS system and Motif’s DOT device signal institutional recognition that pharmacological treatment alone isn’t enough for millions of patients. The randomized, double-blind trial designs being used now are specifically designed to answer the placebo question that earlier studies couldn’t. And the shift toward closed-loop, personalized systems represents a genuine conceptual advance over the blunt-instrument stimulation of previous decades.

For a broader view of how consumer and clinical neurotech is converging on mental health, the NeurotechMag piece How Neurotech Is Quietly Replacing Antidepressants for Some Patients tracks how the whole field is moving at once — from surgical implants down to at-home headsets — and why the pace is accelerating.

The short-term markers to watch: 🚀

• TRANSCEND trial readout: Abbott’s pivotal DBS data, expected in the late 2020s, will likely determine whether the FDA approves an indication specifically for depression, which would be a watershed moment for psychiatric neuromodulation

• Motif RESONATE safety data: The 12-month safety and early-efficacy results will tell us whether minimally invasive over-brain stimulation is viable at human scale

• Closed-loop biomarker research: The race to identify reliable, individualizable neural signatures of depressive states is probably the key scientific bottleneck — whoever cracks it accelerates everything else

• Insurance and reimbursement policy: The clinical pipeline is ahead of the coverage pipeline. That gap will define whether any of this reaches the patients who need it most

I keep thinking about something Brian Kopell, the lead neurosurgery investigator for TRANSCEND, said: that it is not surprising DBS is showing promise for depression, given how clearly we can now see the structural and functional brain changes that define this condition. Once you reframe depression as a brain circuit disorder rather than a mysterious mood state, the neurostimulation approach stops sounding radical and starts sounding like neurology catching up with itself.

The real question isn’t whether electrical stimulation can treat depression — the early evidence says it can, at least for some people. The question is whether we can deliver it safely, personalize it effectively, make it available equitably, and do all of that before another decade passes for the millions of people for whom the pill bottle has already failed.

So I’ll leave you with this: if you were in the position of having failed four antidepressant treatments and someone offered you a 20-minute outpatient procedure to place a blueberry-sized device in your skull — would you do it? And what would need to be true about the evidence before you said yes?

There’s a version of neurotech news that reads like a highlights reel. Monkey plays Pong with its mind. Paralyzed man controls cursor by thought. Patient types with brain signals alone. These headlines are real, and the science behind them is legitimate. What rarely makes the reel is everything that happened before the headline: the years of bench tests, the animal surgeries, the regulatory submissions, the clinical holds, the software fixes, the re-submissions, the pivotal trials that haven’t started yet.

That gap between “lab breakthrough” and “thing you can actually buy” is enormous, and most neurotech coverage treats it like a footnote. It isn’t. Understanding it tells you why no implantable BCI is commercially available to the general public today, despite a decade of stunning demonstrations. It tells you why Synchron is still running trials even though its Stentrode device has been in patients since 2021. And it tells you, with some specificity, when any of this might actually reach your neurologist’s office.

The pipeline isn’t a mystery. It’s a sequence of gates, each with its own rules, timelines, and ways to fail. Walk through them once and the “any day now” framing of most BCI coverage becomes a lot harder to sustain — but so does despair, because the pace of progress through those gates is genuinely accelerating.

Stage 1: bench and animal testing — years before any human sees it 🔬

Every neural device starts life not in a skull but on a workbench. Bench testing is the unglamorous foundation: engineers stress-test materials, cycle electrodes through simulated body conditions, confirm the device won’t corrode or short-circuit or heat tissue beyond safe limits. For implantable neurotechnology, the governing standard is ISO 10993, which specifies how biocompatibility must be evaluated. Cytotoxicity, genotoxicity, implantation effects — regulators expect data on all of it before a single animal is touched.

Then come the animal studies. These are not optional for novel implantable devices, and they are not quick. Regulatory guidance from NAMSA, a major preclinical testing firm, published in January 2026 describes the typical progression:

• Small animal studies (rodents, rabbits): used for early biocompatibility, basic electrophysiology, initial signal quality assessments

• Large animal studies (sheep, pigs): required for human-scale devices whose size can’t be miniaturized for rodent anatomy; these test realistic surgical delivery, chronic implantation, and signal stability over months

• Chronic studies: often run for six to twelve months minimum, because a device’s performance at week two tells you almost nothing about week forty

This phase easily runs two to five years, depending on how many design iterations the data triggers. Neuralink famously ran extensive primate studies before its first human trial in 2024 — studies that drew significant criticism over animal welfare but that produced years of chronic recording data that informed the N1 implant design. 🧠

The output of all this is a preclinical data package that will become the backbone of every regulatory submission that follows. Skip a study or run it poorly and the FDA will notice.

Stage 2: the IDE — permission to try it in humans ⚡

With preclinical data in hand, a company can apply for an Investigational Device Exemption (IDE). This is the document that lets a device that isn’t approved for sale be used in a clinical study. Without it, implanting an experimental BCI in a patient is illegal. The FDA’s IDE program requires both FDA sign-off and approval from an Institutional Review Board (IRB) at each participating hospital before a single patient can be enrolled.

The FDA has 30 days to respond to an IDE application for a significant-risk device. That sounds fast. In practice, companies often go through multiple rounds of requests for additional information, and the path to IDE approval can stretch considerably longer. Neuralink learned this directly: the FDA placed a clinical hold on its application in 2022 over concerns about device reliability, battery safety, wireless data integrity, and explantation planning. The company spent roughly 10 months addressing those concerns before getting the green light in 2023.

Once an IDE is approved, the first human studies are Early Feasibility Studies (EFS) — small trials, typically six to ten patients, designed primarily to answer a safety question: does this device do anything catastrophically bad when implanted in a human? Synchron’s COMMAND trial, the first IDE-approved study of a permanently implanted BCI in the US, enrolled six patients. Paradromics received its IDE for speech restoration in November 2025. These are not “is it working well enough to sell” studies. They’re “does it cause brain hemorrhage or death” studies. The bar is different. 💡

What helps enormously at this stage is a Breakthrough Device Designation, a separate FDA program that enables faster communication with the agency, more frequent feedback, and some flexibility in evidence requirements. As of December 31, 2025, the FDA had granted 1,246 Breakthrough Device designations total. Multiple BCI companies hold the status, including Synchron (for ALS), Paradromics (twice), and CorTec (for stroke rehabilitation). Critically, it does not guarantee a faster time to market. It accelerates the conversation, not the biology.

Stage 3: pivotal trials — the real test, and the long one 📈

Passing an Early Feasibility Study means you’ve shown your device probably won’t kill people in a small sample. That is necessary. It is nowhere near sufficient for commercial approval. What comes next is the pivotal trial: a larger, controlled study with statistically justified enrollment, designed to produce definitive evidence that the device’s benefits outweigh its risks for a specific population and indication.

Pivotal trials for complex implantable devices typically run two to four years, because chronic safety data — what happens at six months, at twelve, at twenty-four — takes that long to generate by definition. Synchron CEO Tom Oxley said publicly in late 2024 that his company was in conversations with the FDA about pivotal trial endpoints, and that such a trial would “take a couple years to run” before submission for PMA. His company completed its COMMAND feasibility study in September 2023, with all six patients meeting primary safety endpoints at twelve months. Pivotal enrollment likely hasn’t even begun. 🔬

The regulatory submission at the end of a successful pivotal trial is a Premarket Approval application (PMA), which is the FDA pathway for Class III high-risk devices. The FDA classifies most implantable BCIs as Class III, meaning the PMA pathway applies. A PMA requires clinical evidence of safety and effectiveness — not just absence of harm, but proof the device actually does what it claims. Review of a PMA application typically takes six to twelve months. If the FDA issues a “major deficiency letter” (which is common), that clock resets.

There is one other pathway worth knowing: the 510(k), which clears a device by showing it’s substantially equivalent to a predicate device already on the market. This is a lower bar than PMA, appropriate for lower-risk or less-novel devices. Precision Neuroscience used the 510(k) pathway to receive clearance for its Layer 7 Cortical Interface in April 2025, by establishing equivalence to an existing subdural electrode system. That clearance authorizes the Layer 7 for commercial use — but only for implantation up to 30 days, specifically for surgical mapping applications. It is not authorization for a chronic, permanent BCI. The distinction matters enormously.

Stage 4: what “approved” still doesn’t mean 🧬

Here is where the story gets underappreciated. Obtaining FDA approval or clearance for a device does not mean patients can access it. There are at least three more major barriers that can stall a device in the post-approval phase for years.

Reimbursement is the first and often most underestimated. If insurance doesn’t cover a device, the effective price to patients is whatever the device costs plus the surgical implantation plus the follow-up care. For complex brain devices, that’s likely to be tens or hundreds of thousands of dollars. The failure of Second Sight’s Argus II retinal prosthesis is the cautionary tale here: the device received regulatory approval, but struggled commercially partly because of reimbursement challenges and high procedural costs, ultimately leading to market withdrawal. China is handling this more proactively: in 2025, China’s National Healthcare Security Administration added BCI implantation procedures to its list of reimbursable services, with Hubei Province becoming the first to release official BCI pricing. The US has no equivalent framework yet.

Surgeon training is the second barrier. A BCI implant is not a device that any neurosurgeon can pick up on Monday and deploy on Wednesday. Neuralink’s robotic implantation system requires specific training. Precision Neuroscience’s micro-slit delivery approach is technically demanding. Building a trained surgical workforce takes years, and it scales slowly.

Manufacturing at scale is the third. A device that works in 20 patients does not automatically work when you need 2,000. Thread uniformity, electrode yield rates, sterile packaging at volume — these are genuine engineering challenges that have derailed medtech launches before.

None of this is a reason to be pessimistic. Based on what’s publicly known, the most realistic estimate for a first full PMA approval of an implantable BCI in the US is probably the late 2020s, with Synchron and Neuralink as the likeliest candidates. That timeline assumes no major trial failures, no unexpected safety signals that trigger a clinical hold, and reimbursement pathways that keep pace with the technology. That’s several meaningful assumptions.

The neurotech tipping point piece published by NeurotechMag in February 2026 described this moment as the transition from theoretical potential to realistic, impactful technology. I’d add a qualifier: the transition is happening on the regulatory side, not yet on the commercial side. Dozens of real human trials, two major 510(k) clearances, a string of Breakthrough designations, a Morgan Stanley BCI market valuation of $400 billion — these are not nothing. They’re just not living rooms yet.

Think about where cochlear implants are today: routine, widely reimbursed, implanted in hundreds of thousands of patients, covered by most major insurers. The first cochlear implant received FDA approval in 1984. Widespread adoption didn’t materialize until the mid-1990s. That’s ten to fifteen years between approval and routine. BCIs are earlier in that arc, not further.

So here’s the question worth thinking through: what would need to be true — technically, commercially, politically — for the first BCI to reach a neurology clinic near you by 2030? Work backwards from that date, and you can see exactly which of the gates described above is the longest pole in the tent right now.

Imagine paying for a state-of-the-art brain-computer interface, having the surgery, recovering, and then watching it gradually go silent over the following months. Not because the hardware broke. Not because the software crashed. But because your own brain, doing exactly what it’s designed to do, decided the device was a foreign invader and began methodically walling it off.

That’s not a hypothetical. It’s one of the central unsolved engineering problems in neurotechnology, and it goes by the name glial scarring. Until researchers crack it, every promising advance in BCIs — from Neuralink’s electrode threads to next-generation speech decoders — runs into the same biological wall.

The strange part is that the brain isn’t malfunctioning when it does this. It’s functioning perfectly. The immune response to implanted devices is exactly the right response to a foreign object — it just happens to be catastrophic for the electronics inside your skull. Understanding why that happens, and what engineers are doing about it, tells you a lot about why brain implants are harder than they look and why the field is closer to a real solution than most people realize. 🧠

The body’s most efficient walling-off machine 🔬

The moment a surgeon inserts a neural probe into brain tissue, a timer starts. Within 30 minutes of implantation, microglia — the brain’s resident immune cells — are already extending processes toward the device. By the two-hour mark, they’ve covered roughly half the probe’s surface. Within about 20 hours, astrocytes join in, swelling and extending their own processes toward the implant. Within days, a dense cellular sheath has begun to form around the electrode.

This process, called the foreign body response, is coordinated in phases:

• Acute phase (first hours): microglia detect the implant as a threat, extend toward it, and begin releasing inflammatory cytokines including TNF-α and interleukin-1

• Subacute phase (days to weeks): activated astrocytes upregulate a protein called GFAP (glial fibrillary acidic protein), proliferate, and migrate toward the injury site

• Chronic phase (weeks to months): the glial scar densifies, neurons near the electrode begin dying or retreating, and a thick insulating sheath of reactive cells permanently encapsulates the device

A 2025 review published in the Journal of Neurochemistry by Paveliev and colleagues captures the timeline in uncomfortable detail: astrocyte morphology changes toward a reactive phenotype within one hour of insertion, and the number of astrocytic processes wrapping toward the probe steadily increases from 6 hours to 7 days post-implantation.

The biological logic is sensible. Your brain is the organ that most needs protection from infection and foreign material — it sits behind the blood-brain barrier for a reason, and when that barrier breaks (as it does when a probe is inserted), the immune response kicks in hard. The problem is that neurons retreat from the scar tissue, increasing the distance between the electrode and the cells it needs to record from. The scar itself is electrically insulating. Signal quality drops. Then it drops more. Then, eventually, the signal is gone. 😔

Why the Neuralink thread problem wasn’t just bad luck ⚡

Neuralink’s first patient, Noland Arbaugh, became the most publicly scrutinized test case for neural electrode longevity in history. The early results were striking: Arbaugh was controlling a computer cursor, playing chess, and eventually learning new languages entirely through thought-based input. Then, about three months post-surgery, reports emerged that approximately 85% of his 1,024 electrodes had retracted from brain tissue, sharply reducing signal capture.

Neuralink traced part of the problem to brain micromotion — the constant, subtle movement of brain tissue inside the skull that turns out to be about three times greater than the company’s engineers had anticipated. When an electrode is stiffer than the surrounding tissue, even tiny movements create mechanical stress at the interface, which the brain reads as ongoing injury and responds to with ongoing inflammation. More inflammation means more scar tissue. More scar tissue means more signal loss.

The company ultimately resolved Arbaugh’s performance degradation through software — recalibrating the decoding algorithm to extract useful signal from the remaining active electrodes — rather than anything biological. Which is clever engineering, but it’s not a fix for the underlying problem. It’s more of a workaround.

This gets at something worth thinking about: the stiffness mismatch between silicon or metal electrodes and brain tissue is enormous. Silicon has a Young’s modulus of roughly 180 GPa. Brain tissue sits somewhere between 1 and 30 kPa — that’s approximately ten billion times softer. Flexible polymer materials like polyimide (1.5–2.5 GPa) are a significant improvement, but even they remain orders of magnitude stiffer than the tissue they’re sitting in.

Does this make you rethink what “biocompatible” really means for neural devices? Because biocompatible in the chemical sense — the material doesn’t leach toxic compounds — turns out to be a much lower bar than biocompatible in the mechanical sense. Your brain doesn’t care if the probe is inert. It cares that there’s something rigid poking through it.

The engineering counter-offensive 💡

The good news is that materials scientists, neuroscientists, and device engineers have been attacking this problem from multiple angles, and several approaches are starting to produce real results.

Soft and flexible probes are probably the most active research front right now. The fundamental idea is to match the mechanical properties of the electrode to those of brain tissue, reducing the micromotion-induced stress that signals ongoing injury. Research on ultraflexible probes — reported in Science Advances — found that drastically reducing bending stiffness could essentially eliminate glial scarring in animal models. Precision Neuroscience’s Layer 7 Cortical Interface, which received FDA clearance in April 2025 as the first wireless BCI device to get that status, takes a different but related approach: rather than penetrating the cortex at all, its 1,024-electrode flexible film sits on the brain’s surface, threading through a cranial micro-slit smaller than 1 mm. No penetration means no initial puncture injury. No initial puncture injury means a much quieter immune response.

Drug-eluting coatings are the second major strategy. The idea is to coat electrodes with materials that slowly release anti-inflammatory compounds directly at the tissue interface, suppressing the immune response locally without systemic effects. One well-studied approach uses PEDOT (poly(3,4-ethylenedioxythiophene)), a conductive polymer that can be loaded with drugs like dexamethasone and triggered to release them electrically. It solves two problems at once: it improves the electrode’s electrical properties by reducing impedance, and it fights the inflammation that would otherwise degrade the interface over time.

A 2024 study in the RSC Journal of Materials Chemistry B described injectable PEDOT-based hydrogel electrodes that can be delivered in liquid form and solidify in place — meaning the electrode conforms perfectly to the brain’s irregular surface rather than pushing against it. The potential implications for reducing mechanical mismatch and therefore inflammation are meaningful.

Lubricant-coated probes are a newer entrant. Research published in ACS Applied Bio Materials in early 2026 described flexible printed circuit board probes with a biocompatible lubricant coating, which showed markedly reduced astrocytic and microglial activation in chronic mouse implants compared to uncoated probes, with stable neural signals maintained for several weeks.

Shrinking the probe itself also helps. MIT researchers have shown that reducing electrode diameter can dramatically reduce scarring, because a smaller probe displaces less tissue during insertion and generates a smaller ongoing mechanical stimulus. About half of standard deep brain stimulation electrodes stop working within the first six months, partly because the constant rubbing of a millimeter-scale electrode generates persistent gliosis. Microscale probes change that calculus. 🔬

The surface vs. penetrating tradeoff

Not everyone agrees that penetrating the cortex is the right approach for long-term chronic recording. This debate is worth paying attention to, because it’s not just a technical disagreement — it’s a fundamentally different hypothesis about where the longevity problem is solvable.

Penetrating electrodes like Neuralink’s threads get very close to individual neurons, which gives you high-resolution single-unit recordings. That’s genuinely valuable. But they also punch through cortical tissue, rupture blood vessels during insertion, and create a chronic micromotion problem that doesn’t go away. The foreign body response for penetrating electrodes is substantially more aggressive than for surface devices.

Surface or subdural electrodes — like Precision Neuroscience’s Layer 7 or classic electrocorticography (ECoG) arrays — avoid the penetration problem entirely. They record from the cortical surface rather than inside the tissue. Signal resolution is lower at the single-neuron level, but the absence of tissue penetration means a much milder immune response, and the Layer 7’s 1,024-electrode density compensates significantly by giving you high spatial resolution across a wide area.

The tradeoffs look roughly like this:

• Penetrating cortical electrodes: highest single-neuron resolution, fastest signal degradation, most intense foreign body response, most surgically invasive

• Surface cortical arrays (ECoG/Layer 7): lower single-neuron resolution, milder foreign body response, commercially cleared, reversible and modular

• Soft/flexible penetrating probes: promising middle ground, reduced mechanical mismatch, still in pre-clinical or early clinical stages for most designs

• Drug-eluting coated electrodes: add-on strategy applicable to multiple device types, effectiveness varies by drug, delivery mechanism, and timescale

Precision Neuroscience’s co-founder Benjamin Rapoport, MD, PhD, who previously left Neuralink in part over concerns about the long-term consequences of penetrating electrodes, built Layer 7 explicitly around the reversibility and surface-access philosophy. He’s basically betting that the longevity problem is easier to solve if you stay out of the cortex in the first place.

That might be right. Or it might turn out that the signal resolution you lose by staying on the surface limits what’s therapeutically possible. The field doesn’t have a definitive answer yet, and that ambiguity is probably where the most interesting research is happening right now. 🧬

What “solved” would actually look like 📈

It’s worth being honest about what “solving” the glial scarring problem requires. Eliminating the foreign body response entirely is probably unrealistic — the brain’s immune system is deeply wired to respond to foreign objects, and suppressing it systemically would create serious infection risks. What researchers are hunting for is something more specific: a stable, low-inflammation long-term interface where the scar either stops forming at a level that doesn’t impair signal quality, or is managed close enough to the electrode surface that the electrode still has access to active neurons.

The benchmarks the field is working toward include:

• Maintaining useful signal quality for five or more years post-implantation in chronically implanted devices

• Reducing astrocyte and microglia activation to levels where nearby neurons don’t die or retreat

• Eliminating the acute-insertion trauma that triggers the most intense early inflammatory response

• Developing materials that are mechanically indistinguishable from brain tissue, not just electrically inert within it

None of those is fully solved. Some are closer than others. The soft-probe and lubricant-coating work is producing real reductions in scarring in animal models. The surface-access approach of Layer 7 sidesteps the penetration problem in ways that have been validated in 37 clinical study participants. Neuralink’s algorithmic workaround for Arbaugh’s retracted electrodes worked, even if it didn’t address the biology.

What’s actually exciting — and I think this is the underappreciated story here — is that the field is now attacking the problem with a level of materials sophistication and mechanistic understanding that didn’t exist five years ago. Researchers know exactly when microglia start moving (within 30 minutes), when astrocytes activate (within an hour), how the two cell populations coordinate via cytokine signaling, and which mechanical properties of the electrode most predict long-term scarring severity. That mechanistic clarity is what makes better solutions possible.

The brain is extraordinarily good at protecting itself from things that don’t belong inside it. Building something that does belong — or at least convinces the brain it does — is the problem. And given how fast materials science and neural engineering are both moving right now, my guess is it’ll look solved within a decade. At which point the question becomes: what do we actually want these implants to do when they can last a lifetime?

That’s the conversation worth starting now.

Not long ago, “mind reading” belonged to carnival acts and bad sci-fi. Today it belongs to Nature Communications Biology, MIT preprint servers, and a growing number of research labs where scientists feed raw electrical brain signals into large language models and watch readable text come out the other side. What changed? Mostly, the AI got a lot better. The brain hasn’t changed much in the last few hundred thousand years, but the tools we’re using to interpret it have transformed almost beyond recognition.

Neural decoding — the science of translating brain activity into usable information — has been around since the 1990s in primitive form. What’s new is the marriage of that field with modern deep learning, and the results are genuinely startling. We’re not talking about detecting whether someone is happy or sad. We’re talking about reconstructing the specific sentence a person is silently reading, or generating a photorealistic image of what they’re looking at, straight from the wobble of blood oxygenation in their visual cortex. This is not a metaphor. It’s happening now.

So how does it actually work? And what does it mean that a machine can — sort of, sometimes, imperfectly but impressively — read your mind?

The basic problem: the brain is a noisy place 🧠

The first thing to understand is that reading neural activity is nothing like reading a hard drive. The brain generates billions of signals simultaneously, most of them redundant, many of them corrupted by movement artifacts, electrical interference, or just the ordinary chaos of biological tissue doing its thing. Getting a clean signal out of that environment is hard. Getting meaning out of that signal is, or was, even harder.

The two main non-invasive tools researchers use are:

• fMRI (functional magnetic resonance imaging): measures blood flow as a proxy for neural activity, with excellent spatial resolution but terrible time resolution — roughly one snapshot every two seconds

• EEG and MEG (electro- and magneto-encephalography): measures electrical and magnetic fields from neurons firing, capturing millisecond-by-millisecond changes but with much murkier spatial precision

Each has real trade-offs. fMRI tells you where something is happening in the brain with reasonable clarity. EEG and MEG tell you when with great precision. Neither, by itself, gives you the whole picture.

What deep learning brought to the table was a way to extract signal from noise at a scale no human analyst could manage. A convolutional neural network trained on thousands of hours of brain recordings learns to recognize patterns that would be invisible to the naked eye — subtle correlations between, say, the activity in your visual cortex and the color red, or between your motor planning areas and the letter “T.” The models don’t understand meaning in any philosophical sense. They learn statistical associations at a frightening level of detail, and that turns out to be enough to do something that looks a lot like reading. 🔬

What’s the most surprising thing about this process to you — that it works at all, or that it works so accurately? Think about that as we go deeper.

From matching to generating: the LLM revolution in brain decoding 💡

For most of neural decoding’s history, the approach was essentially a matching game. You’d train a model on a fixed set of possibilities — say, 50 words or 10 images — and then ask it to pick which one matched a given brain state. Useful for research. Not useful for a patient who needs to say something that wasn’t in the training set.

The shift came when researchers started coupling brain decoders with large language models. In March 2025, a team published BrainLLM in Communications Biology, a system that uses fMRI signals not to select from pre-generated candidates but to directly steer the generation phase of a language model. Feed it the brain recording, and it generates coherent language from scratch — not by picking from a list, but by actually producing novel text aligned with what the brain was processing. The system got stronger as the training datasets grew larger, which suggests that more brain data really does make these models meaningfully better.

Around the same time, Meta AI published Brain2Qwerty, a deep learning architecture trained on MEG and EEG signals from 35 participants who typed memorized sentences. With MEG data, the model achieved a character error rate of 32% on average — and for the best-performing participants, that dropped to 19%, meaning the system correctly decoded roughly four out of five characters without any implant, without any surgery, just from magnetic field fluctuations measured outside the skull. With EEG, the error rate jumped to 67%, which highlights a real gap in the technology that researchers are actively trying to close.

The key insight from Brain2Qwerty is that motor planning signals — the neural activity that precedes physical movement — are surprisingly readable, even when the movement itself is subtle. The brain starts preparing to type a letter before the finger actually moves, and that preparatory activity carries enough information for a well-trained model to make a good guess.

Visual decoding has followed a parallel trajectory, arguably even more dramatic. Researchers have combined CLIP-style semantic embedding (the same technology that powers image-text models) with diffusion model generation to reconstruct images directly from fMRI signals. Someone looks at a photograph. The model reads their visual cortex. It generates an image. That image, in the best experiments, looks recognizably like what the person was looking at — not pixel-perfect, but capturing the semantic content, the objects, the scene structure, with accuracy that has improved dramatically between 2023 and 2025.

Going non-invasive: the MEG and EEG frontier ⚡

The loudest names in brain-computer interface news are invasive. Neuralink, which had implanted its chip in 21 human patients as of January 2026, uses electrodes physically threaded into the cortex. The resolution is extraordinary — 1,024 electrodes on 64 threads thinner than a human hair, giving access to the kind of clean, high-resolution signal that makes decoding relatively straightforward. Noland Arbaugh, Neuralink’s first patient, has used his implant to play chess, browse the web, and learn languages, all through thought-controlled cursor movement.

But the vast majority of people who could benefit from neural decoding aren’t going to elect brain surgery. This is why the non-invasive frontier matters so much, and why the progress there is arguably the more important story.

Meta’s research team at Neurospin has demonstrated that MEG alone, paired with a well-designed contrastive learning model, can identify speech segments from brain recordings at up to 80% accuracy in the best participants — identifying specific speech clips from a pool of over 1,000 candidates with no implant required. A separate Meta team working on decoding individual words from EEG and MEG evaluated their pipeline across 723 participants, reading or listening to five million words across three languages — probably the largest non-invasive brain decoding study ever attempted, and the results show consistent improvement with more data.

The realistic comparison right now looks roughly like this:

• Invasive BCIs: character error rates below 5%, real-time output, but require neurosurgery

• MEG-based decoding: roughly 19–32% error rates in the best cases, not yet real-time, requires a $2 million room-sized machine

• EEG-based decoding: error rates above 60%, but cheap, wearable, and potentially scalable

MEG is impressive but impractical for most people right now — those machines cost up to $2 million and require magnetically shielded rooms. EEG is cheap and portable but still producing error rates that would make the technology frustrating to use in practice. The middle path researchers are hunting for is probably some combination of better hardware miniaturization and better AI models trained on much larger datasets. And given how quickly both have improved in the last three years, dismissing that middle path seems unwise.

When the decoder gets a password 🔐

One of the more quietly remarkable developments in 2025 came from a study published in Cell about a brain implant that can decode internal speech — what you’re saying to yourself, silently — but only if the user first thinks of a preset password. The security model is deliberate: the device stays inactive until it recognizes the authorization pattern, and then starts decoding. It’s a fascinating inversion of normal security thinking. Usually we protect devices from the outside. Here, the researchers are protecting the brain from the device.

This matters because the ethical dimensions of neural decoding have started generating serious regulatory attention, and for good reason:

• A 2024 audit by the Neurorights Foundation found that 96.7% of consumer neurotechnology companies reserve the right to transfer brain data to third parties

• In 2024, Colorado and California became the first U.S. states to explicitly protect neural data under privacy law, with at least six more states following

• In September 2025, senators Schumer, Cantwell, and Markey announced the MIND Act — the Management of Individuals’ Neural Data Act — which would cover both implanted BCIs and wearable neurotech

• UNESCO adopted sweeping global standards on neurotechnology ethics in Paris in November 2025, treating neural data as a special category requiring explicit guardrails

The concern isn’t hypothetical. Neural data is not like a browsing history or a location trace. It encodes emotional states, health conditions, cognitive patterns, and potentially — as decoding technology improves — actual thoughts. The brain has been, until very recently, the last genuinely private space. Once a decoder is accurate enough to capture something approaching inner speech, that assumption evaporates.

Here’s the question worth sitting with: if a company can read your internal monologue through a consumer headset, does your right to remain silent still mean anything?

What this actually gets right — and what it still gets wrong 📈

Neural decoding in 2025 is genuinely impressive and also genuinely limited, and it’s worth being clear about both. The technology gets a lot of press framing that makes it sound more complete than it is.

The real strengths:

• Reconstructing perceived content (images you’re looking at, sentences you’re reading) is substantially more accurate than reconstructing imagined or internally generated content

• Performance scales with data — more training examples, more participants, better results

• Invasive methods have reached speeds and accuracy levels that are practically useful for patients with communication impairments right now

The real limitations:

• Most systems are highly subject-specific — a model trained on your brain activity doesn’t automatically work on someone else’s

• fMRI, the most powerful tool for spatial decoding, costs thousands of dollars per session and can’t be used in real time

• Open-ended language reconstruction (generating whatever a person is thinking about, freely, without constraints) remains an unsolved problem — current systems work best when the possible outputs are constrained or the content is being actively perceived rather than internally generated

• EEG-based systems are far less accurate than MEG or invasive methods, though they’re the only realistic consumer technology in the near term

The neuroscientist Christopher Rozell of Georgia Tech put it plainly at the Society for Neuroscience’s 2025 annual meeting, calling AI “deeply integrated into neuroscience” and noting that it enables “new discoveries and therapies by allowing us to identify patterns and mechanisms that were invisible before.” That’s accurate. What’s also accurate is that the gap between “identifying patterns” and “reading your mind” is still large enough to matter.

The field is moving fast enough that it’s probably worth keeping an eye on it regardless of whether you’re a patient, a researcher, a policy maker, or just someone who’d like to understand what happens to the concept of mental privacy when fMRI gets cheap and portable. That day may be further away than the headlines suggest — or it may not. Given how wrong similar predictions about AI capabilities turned out to be over the past decade, epistemic humility seems warranted.

What do you think the right line is between using neural decoding for medical benefit and protecting people from having their thoughts read without meaningful consent? It’s one of the more important design questions the next decade will have to answer.

Elon Musk gets the press. Nine patients, a surgical robot, and a PR machine that makes every trial feel like a moonshot. Meanwhile, on the other side of the planet, a 30-year-old NeuroXess co-founder named Tiger Tao is quietly letting patients play video games with their minds, a quadriplegic man in Shanghai is steering a wheelchair outdoors using only his thoughts, and a company called BrainCo just completed the second-largest BCI financing round in global history, trailing only Neuralink itself. China’s BCI sector raised over 5 billion yuan (roughly $700 million) in financing rounds in 2025 alone, according to VCBeat’s tracking. The silence from Western media is not because nothing is happening. It’s because the story is harder to tell from a distance, and the companies involved rarely show up at SXSW.

China’s BCI industry is not just a “catching-up” story. That framing is lazy and increasingly inaccurate. In March 2026, China became the first country in the world to approve an invasive BCI device for commercial use — a coin-sized wireless implant by Shanghai-based Neuracle Medical Technology, designed for patients with spinal cord injuries. First in the world. Not a trial. Not an exemption. A commercial product you can prescribe. The US still hasn’t done that. This detail somehow failed to generate the breathless coverage it deserves. If Neuralink had done it, every tech outlet in the Western hemisphere would have led with it for a week.

The pieces of what’s happening in China — the startups, the government infrastructure, the clinical milestones, the funding rounds, the national roadmaps — don’t get assembled into a coherent picture often enough. This is an attempt to fix that.

The companies you should actually know

China has an estimated 170+ BCI companies operating as of 2024, according to CCID Consulting data cited in BioSpectrum Asia. Most of those are small. A handful matter enormously. 🧠

NeuroXess is arguably the most technically ambitious of the lot. Founded in 2021 — yes, just five years ago — by the same Phoenix Peng who later founded ultrasound BCI startup Gestala, NeuroXess specializes in flexible, high-channel implantable electrodes. The company made global headlines when it worked with Huashan Hospital and the Tianqiao and Chrissy Chen Institute to decode a patient’s thoughts into Chinese text in real time — delivering what researchers called the world’s first New Year’s greeting sent entirely via thought. “2025 Happy New Year,” composed in a patient’s mind, appeared on a screen and commanded a robotic arm to make a heart gesture. That’s not a stunt. That’s clinical language decoding in a human patient. In April 2025, NeuroXess disclosed a separate collaborative project implanting a 256-channel flexible BCI in an epilepsy patient that enabled complex video game control — another milestone in the same 12-month window.

StairMed Technology is building toward the most aggressive clinical timeline in the Chinese invasive BCI field. The Shanghai company raised $48 million in a Series B in February 2025, then followed up with another $72.8 million in April 2026, bringing its total fundraising to over RMB 1.1 billion (~$160 million) in under a year. That’s a fundraising pace that would be remarkable anywhere in the world. StairMed’s implant uses a 3-to-5 millimeter cranial puncture to place its sensor 5-8 millimeters into the brain — a design the company says reduces foreign-body sensation while preserving signal quality. The company is now planning large-scale multicenter registration trials targeting 40 patients in 2026, with formal clinical trials expected in 2027. Tencent is a core investor. Alibaba and SDIC Unity Capital joined the most recent round. When a BCI startup has two of China’s biggest tech conglomerates on its cap table, it is not a research curiosity. It is a product pipeline.

BrainCo operates at a different layer entirely — the consumer and medical device intersection. Founded in 2015 at the Harvard Innovation Lab by Han Bicheng, the Hangzhou company has pushed consumer-oriented brain devices to 100,000 units and just completed a CNY 2 billion ($286 million) financing round, the largest BCI investment globally outside of Neuralink. BrainCo has quietly filed for a Hong Kong IPO, and in January 2026 it received approval for its FocusJoy medical edition — an EEG-based ADHD intervention product for children. That’s a regulated medical device for pediatric attention disorders, already approved, already in the Chinese market.

Other names worth tracking:

• NeuCyber Neurotech, a Beijing Institute for Brain Research startup with its Beinao-1 semi-invasive chip, which has completed seven human implantations and aims to expand trials to 50 patients

• Neuracle Medical Technology, the first company anywhere in the world to receive commercial approval for an invasive BCI, a point worth repeating 📈

• Gestala, Phoenix Peng’s second company, which raised $21 million in March 2026 for ultrasound-based non-invasive BCI — a potential next-generation modality that avoids the limitations of both EEG and implants

What’s your read on this field — are Western neurotech investors underestimating China’s BCI ecosystem, or is the technical gap still wide enough that the US companies maintain a meaningful lead?

The policy machine that built this

This didn’t happen organically. China’s BCI acceleration is not a story of scrappy entrepreneurs defying institutional inertia — it is institutional. The government didn’t just notice BCI and issue a supportive white paper. It built a supply chain strategy, coordinated seven ministries, tied funding to specific technical milestones, and connected regulatory approval directly to national insurance reimbursement. 🔬

The Georgetown Center for Security and Emerging Technology has documented China’s key 2025 BCI policy directive in detail: in August 2025, the Ministry of Industry and Information Technology joined six other central agencies to release the Implementation Opinions on Promoting Innovation and Development of the Brain-Computer Interface Industry. Seven ministries. One coordinated document. The goals are specific and timed:

• By 2027: achieve international-level performance in BCI electrodes, chips, and integrated systems; complete clinical trials on two to three flagship products; create three to five unicorn-status companies

• By 2030: establish a full domestic BCI supply chain; produce two to three “world-class” BCI enterprises; bring invasive BCI to commercial scale

The December 2025 Shenzhen BCI Expo added 11.6 billion yuan ($165 million) in a dedicated brain science fund to support companies across the research-to-commercialization pipeline. Shanghai’s municipal government separately released a 2025–2030 BCI action plan in January 2025. Sichuan province published its own roadmap the following May. Guangdong, which now hosts approximately 80 key BCI enterprises, issued its own cultivation plan in 2024. These are not overlapping bureaucratic documents. They are coordinated policy layers at national, provincial, and municipal levels, all moving in the same direction at once.

The funding point is actually the less important innovation here. The more consequential structural difference between China’s BCI policy environment and the US one comes down to insurance reimbursement. Phoenix Peng, in a detailed TechCrunch interview from February 2026, explained the asymmetry precisely: in China, once the state approves a device, national health insurance covers it across the country essentially simultaneously. In the US, FDA approval is just the beginning — then each private insurer must individually decide whether to cover a device, a process that can take years and still produce inconsistent results. The IpsiHand BCI for stroke rehabilitation is a perfect example: FDA-cleared in 2021, it only got its first Medicare billing code in 2024, and major private insurers still classify it as investigational. In China, the regulatory-to-reimbursement pipeline runs faster by design. That’s not a criticism of the US system; it’s an observation about competitive dynamics with real consequences for which market these companies prioritize first.

The national BCI standard Medical Device Terminology for BCI Technology (YY/T 1987-2025) entered enforcement on January 1, 2026, giving China’s regulator a legal foundation to put BCI devices on a “regulatory fast track.” These are not vague aspirational documents. They are the architecture of a commercialization machine. 🚀

What the gap actually looks like — honest version

Here’s where the picture deserves some precision. China’s BCI ecosystem is real, fast-growing, and increasingly competitive. It is not technically ahead of the US across the board, and the most credible voices in the Chinese BCI field say so directly.

Li Yuan, rotating CEO of NeuCyber, told Reuters in March 2026 that the company’s frontier Beinao-2 product — its fully invasive system with flexible electrodes — is still roughly three years behind Neuralink. Neuralink has over 20 patients in active trials. Beinao-2 is still in large-scale animal testing. That is a concrete, honest self-assessment, and the gap it describes is real.

The places China is genuinely competitive, or even ahead: 🔬

• Semi-invasive and flexible electrode designs: Chinese teams at NeuroXess and CAS have advanced the engineering of thin, biocompatible electrode arrays that may cause less chronic tissue response than stiffer devices

• Clinical trial volume: with over 50 flexible implantable BCI trials completed by mid-2025 across Chinese hospitals, and a patient pool that is larger and more accessible than in the US, China may accumulate clinical data faster than any other country

• Commercial approval speed: Neuracle’s commercial approval — the first in the world for any invasive BCI — is a regulatory milestone that the US has not yet matched, and it signals that China’s NMPA is prepared to approve these devices while US counterparts are still working through the framework

• Non-invasive consumer scale: BrainCo has shipped consumer devices at a scale Western companies haven’t approached, providing a platform for real-world data accumulation

CNN’s reporting in July 2025 captures the nuance well: US researchers who have reviewed Chinese BCI research describe it as “comparable with that of other scientifically advanced nations” on the non-invasive side, while the invasive work has “picked up pace and is approaching global standards.” The word “approaching” is accurate. Not there yet. Closing fast.

The more complicated question is what the competitive frame even means here. Are we watching two countries race to help paralyzed patients communicate? Or are we watching a geopolitical contest over which country controls the architecture of human-computer interfaces? Probably both, uncomfortably. The US Senate Commerce Committee raised explicit concerns in April 2025 about neural data security and the possibility of Chinese companies using BCI data in ways that implicate national security. UNESCO adopted its first global neurotechnology ethics framework in late 2025. These are real questions. They complicate the straightforward “which country wins” framing, because what winning means for invasive BCI depends heavily on who controls the data that flows through these devices.

Why this matters for the global neurotech arc

The significance of what China is building isn’t just competitive — it’s structural. 💡 If you believe BCI is going to be a major medical and eventually consumer technology in the 2030s, then where the clinical evidence gets generated, where the devices get manufactured, and where the regulatory standards get written matters enormously.

As NeurotechMag has already noted in tracking these signals, high government involvement in neurotech usually means a technology has moved beyond niche research into territory with real economic and societal stakes. The same pattern played out in electric vehicles and solar panels, where China’s industrial policy approach created cost structures and production scales that eventually reshaped the global market. Whether BCI follows that trajectory depends on factors that aren’t fully visible yet — signal quality, biocompatibility at scale, long-term electrode stability, and the still-unsolved question of whether any implantable device works reliably enough for a mainstream clinical population. But the preconditions for that trajectory are being assembled rapidly.

Phoenix Peng’s framing at Gestala is probably the most honest articulation of where this is heading: “China offers large-scale clinical research capacity and efficient supply chains, while the U.S. has world-class scientific talent,” he told TechCrunch. He still hopes for collaboration, despite the geopolitical headwinds. That framing — two complementary strengths, better together — is more useful than a pure zero-sum race narrative. But collaboration requires trust, and trust in neurotechnology is a particularly complicated thing to build when the underlying product is a device that reads your brain.

The projection from CCID Consulting puts China’s BCI market at RMB 5.58 billion (~$780 million) by 2027, growing at 20% annually. Some projections go as high as 120 billion yuan by 2040 under optimistic scenarios. Whether those figures land precisely isn’t the point. The point is that a sector with those projections, backed by seven ministries, with a commercial device already approved and an IPO-ready company in BrainCo, is not a “watch this space” story anymore. It is already a story.

The question for anyone tracking this industry: if Neuracle’s commercial BCI approval in March 2026 — a genuine world first — barely registered in Western neurotech coverage, what else are we missing?

Every year, roughly 800,000 Americans have a stroke. Most survive. Many don’t recover. According to the CDC, stroke is a leading cause of serious long-term disability in the United States, and it reduces mobility in more than half of survivors over 65. The standard playbook after a stroke has always been the same: get the patient into acute rehab as fast as possible, squeeze every possible recovery out of the first three to six months, and then brace for the plateau. “What you regain early on is all you can expect,” neurologists told patients for decades. It was a reasonable summary of the science. It was also, apparently, wrong.

A new category of device is quietly rewriting that script. 🧠 Non-invasive brain-computer interfaces designed for home use are giving chronic stroke survivors — people years or even decades past their event — measurable motor recovery in their own living rooms. No clinic required. No neurosurgeon. No wires through the skull. Just an EEG headset, a robotic exoskeleton on the arm, and the patient’s own brain signals, doing the heavy lifting in ways neurologists didn’t think possible in the chronic phase. The results coming out of 2025 and early 2026 are hard to dismiss. In fact, they’re kind of remarkable.

What “chronic stroke” actually means — and why it matters

Before getting into the devices, it’s worth sitting with the scale of the problem. 🔬 When clinicians talk about chronic stroke, they mean survivors who are more than six months past their event and still living with motor deficits. The arm is physically intact. The muscles work. What’s broken is the communication line between the brain’s motor cortex and the arm itself — the neural pathway that turns “I want to reach for that glass” into an actual reaching motion.

Between 55% and 75% of stroke survivors have lasting motor deficits, and arm function is the hardest to recover. Research compiled from clinical trials shows that 65% of patients at six months are unable to effectively incorporate the paretic hand into daily activities — not because of muscle damage, but because the motor cortex can’t reliably instruct the arm to act. Subjective wellbeing drops sharply one year post-stroke, and the dominant cause is arm impairment, not just general disability.

The rehabilitation gap in this population is stark:

• Most insurance-covered rehab ends within the first few months, when recovery velocity is highest

• The American Heart Association noted in a July 2025 policy statement that U.S. stroke rehabilitation systems “continue to fall short of the needs of patients”

• The economic cost of stroke is projected to increase more than five-fold between 2020 and 2050, from $67 billion to $423 billion — the largest absolute cost increase among any medical condition covered by Medicare

• Forty percent of stroke survivors report being physically inactive one year post-event, a figure that suggests the rehab system is losing people well before they’ve exhausted recovery potential

The dominant assumption has always been that the brain’s neuroplasticity — its ability to rewire after injury — essentially expires after the acute phase. BCIs are challenging that assumption with real data, and the mechanism they exploit is something neuroscientists have understood in principle for years. What’s new is packaging it into something a person can use alone, at home, for an hour a day.

The science of Hebbian learning, and why timing is everything

The biological mechanism behind BCI-driven stroke rehabilitation is called Hebbian plasticity, named after the psychologist Donald Hebb, whose 1949 principle is usually summarized as: “neurons that fire together, wire together.” ⚡ The idea is that when two neural events happen in tight temporal coincidence — the brain’s motor intention and the corresponding sensory feedback from an actual limb movement — the synaptic connection between those neurons strengthens. The brain interprets the coincidence as meaning those circuits belong together, and reinforces the pathway.

The problem in chronic stroke is that the motor cortex tries to signal the arm, but the damaged pathway means the arm never moves. There’s no sensory feedback. The loop never closes. The brain eventually stops trying in any meaningful way, and the pathway degrades further.

A BCI breaks this deadlock. Here’s the sequence, as explained in a 2025 review published in Frontiers in Neurology:

• The patient wears an EEG headset that reads motor cortex activity

• The patient thinks about moving their affected arm or hand — motor imagery, no actual movement needed

• The BCI detects the characteristic pattern of motor intent in the EEG signal, specifically the mu-rhythm desynchronization (8–12 Hz) that appears when the motor cortex “fires”

• The system immediately triggers functional electrical stimulation (FES) — precisely timed electrical pulses that physically move the patient’s paralyzed arm

The physical movement closes the loop. The brain intended movement, and movement happened. Hebbian plasticity interprets this as the pathway working, and progressively strengthens it. Do this repeatedly, session after session, and the motor cortex gradually recruits intact tissue in the ipsilateral hemisphere — the healthy side — to take over the function that the damaged pathway can no longer handle. Recovery in the chronic phase isn’t about healing the damaged tissue. It’s about rerouting around it. 🔬

Research from a longitudinal BCI-FES study published in Science Research confirmed this at a neurological level, showing two synergistic mechanisms at work: Hebbian plasticity-driven neural remodeling and engagement of intact corticospinal tract fibers, mediated by the closed-loop sensorimotor integration the BCI creates. The EEG biomarkers matched: increased functional connectivity between motor areas in the affected hemisphere correlated directly with functional improvement — which is about as clean a cause-and-effect signal as neuroscience gets.

The key word in all of this is contingent. The feedback only works if it’s locked to the patient’s own motor intention, not delivered randomly or on a timer. Studies comparing active BCI-FES to sham FES — where hardware is identical but stimulation is random — consistently show the active group outperforms sham. Intention is the variable that matters. The BCI is the thing that detects it.

IpsiHand and the RCT that changed the conversation

You can have all the mechanistic elegance in the world and still fail to convince anyone in clinical medicine without a randomized controlled trial. That is what February 2026 delivered. 💊

Kandu, the company that formed from the 2025 merger of Neurolutions and Kandu Health, announced results from the first randomized controlled trial of an FDA-cleared, non-invasive BCI therapy in chronic stroke survivors. The findings were presented by Dr. Eric Leuthardt of Washington University School of Medicine at the International Stroke Conference in New Orleans. The numbers landed well.

Patients using the IpsiHand system — Kandu’s EEG-driven, FDA-cleared home BCI — showed significantly greater improvements in upper extremity motor function than those on a standard home exercise program. The number needed to treat (NNT) was 2.2, meaning that for every 2.2 patients who use IpsiHand instead of standard exercises, one patient achieves a clinically meaningful functional benefit. For a chronic neurological condition that clinicians have considered largely treatment-resistant, an NNT of 2.2 is a striking result.

Kandu CEO Leo Petrossian was blunt about what it means: these data, he said, “fundamentally challenge the longstanding belief that recovery after stroke permanently plateaus after the first few months.”

What makes IpsiHand’s regulatory position particularly interesting is how far along the access pathway it already sits:

• FDA clearance: received in 2021 as a Breakthrough-Designated, de novo 510(k) device — the first BCI cleared for stroke rehabilitation

• Medicare billing code: in April 2024, CMS created HCPCS code E0738 specifically for IpsiHand, classifying it as Durable Medical Equipment — making it the first BCI with a dedicated Medicare reimbursement code

• Veterans Affairs coverage: IpsiHand is also covered through VA, which gives access to a large population of younger, working-age stroke survivors

The therapy protocol involves using the device at home for one hour a day, five days a week. The EEG headset picks up motor intent. The robotic exoskeleton moves the affected arm or hand. The patient’s brain does the neuroplasticity work. A clinical team monitors progress remotely through Kandu’s telehealth platform. No clinic visits. No scheduling conflicts. No transportation barriers. That’s not a trivial convenience — for many chronic stroke survivors, especially older adults in rural areas, access to outpatient rehab facilities is genuinely limited.

One hundred percent of participants in Kandu’s earlier clinical trials showed some improvement in arm or hand function. The newer RCT puts statistical rigor behind that signal. If you’ve been following this space and wondering when the evidence would catch up to the mechanism, this is that moment.

The bigger picture: telerehabilitation and what home-based BCI enables

Let’s zoom out. 📈 IpsiHand is today’s most clinically validated home BCI for stroke, but the field around it is moving fast, and the underlying architecture — EEG-detected motor intent, closed-loop feedback, remote clinical oversight — is being applied in multiple directions simultaneously.

The University of Sheffield’s Tele BCI-FES system, studied in a 2025 clinical trial, delivers BCI therapy entirely over telerehabilitation infrastructure. Eight chronic stroke patients completed nine home-based BCI-FES sessions with real-time remote adjustment from the clinical team. Every patient completed the protocol. The research team flagged the key insight: existing rehabilitation methods focus almost entirely on recovery within the first months post-stroke, leaving the chronic population with minimal options. A telerehabilitation BCI changes the economics of who can access therapy — not just the efficacy of the therapy itself.

Virtual reality is entering this space too. Combining BCI motor intent detection with immersive VR environments makes motor imagery training more engaging and, according to several studies, more accurate. When patients visualize movement in a VR scene that shows the arm moving in response to their neural signals, classification accuracy improves. A randomized crossover trial combining BCI with VR for upper limb stroke rehabilitation began recruiting at the Technical University of Lisbon in January 2026, with completion targeted for 2027.

The broader pattern here deserves attention:

• Hebbian feedback quality improves when visual and proprioceptive channels are both engaged — VR provides the visual, FES provides the proprioceptive

• AI-driven signal decoding is getting better at generalizing BCI decoders across patients, reducing the calibration time new users need before therapy is effective

• Closed-loop adaptive systems are replacing fixed-threshold detectors, meaning the device learns the specific patient’s neural patterns rather than applying a generic template

• Remote monitoring allows clinical teams to adjust stimulation parameters, review adherence data, and intervene early if a patient is struggling — without anyone leaving home

None of this is science fiction. Most of it is already in commercial deployment or late-stage trials. What’s missing, still, is scale. Home BCI devices reach a small fraction of the chronic stroke population that might benefit from them, partly because awareness is low, partly because reimbursement pathways are still being established, and partly because neurologists who trained before 2020 were taught that the chronic phase means reduced recovery potential. That teaching needs updating.

Have you or someone you know been told there’s little point in further rehabilitation more than a year after a stroke? Given the IpsiHand RCT results, it might be worth reconsidering that conversation with a neurologist who’s current on BCI-based approaches.

What still needs to work

It would be intellectually dishonest to write about this field without being specific about where the friction points are. The BCI-FES evidence for stroke is genuinely compelling, but it comes with honest caveats. 🔬

The Frontiers in Bioengineering review from 2026 — one of the most comprehensive recent summaries of BCI in severe stroke — notes that “current effect size estimates are limited by small sample sizes, high study heterogeneity, and inherent performance biases.” The RCT from Kandu addresses the rigor concern, but it’s one trial. Replication across more diverse patient populations — different stroke locations, different severity levels, different ages — is still needed.

There’s also a calibration problem that goes underdiscussed: not all stroke survivors produce clean enough motor intent signals for current EEG-based BCIs to reliably decode. Patients with more severe cortical damage, or damage in regions that govern motor imagery itself, may not get the same benefit. The devices currently work best for patients who have some residual motor intent circuitry — the “arm is fine, the connection is broken” population. Patients where the motor cortex itself is substantially damaged face a harder problem.

Insurance coverage is improving but uneven. Medicare and VA coverage exists for IpsiHand, but some major private insurers, including Blue Cross NC as of early 2025, still classify BCI devices as investigational. The RCT data from ISC 2026 will almost certainly accelerate coverage decisions at private payers — this is exactly the kind of evidence coverage reviewers ask for — but there will be a lag.

Finally, adherence over months is different from adherence in a supervised trial. A patient who uses IpsiHand five days a week in a 12-week study with clinical oversight may use it very differently when the trial ends. Kandu’s integration of remote clinical monitoring and its telehealth service model is a deliberate attempt to address this, and the merger with Kandu Health brought in exactly that kind of sustained patient support infrastructure. Whether that translates to real-world adherence comparable to trial performance is something we’ll know more about in 2026 and 2027 as post-market data accumulates.

None of these caveats cancel what the RCT showed. They’re the honest shape of a technology that is real, working, reimbursable, and available — but still early in its commercial lifecycle.

The question worth asking the neurology community right now is sharper than “does BCI rehabilitation work for chronic stroke?” The evidence says it does. The more pressing question is: how many patients who could benefit from this therapy know it exists? If you’re a clinician, a caregiver, or a stroke survivor who has been told recovery has stopped — what would it take to find out whether you’re in the two-thirds who could still meaningfully improve?

The brain race is real. Not the Cold War kind, but something arguably weirder: a genuine, multibillion-dollar sprint to figure out the best way to wire human thought directly into computers. On one side, you have surgeons drilling into skulls to place electrode arrays directly on — or inside — cortical tissue. On the other, you have engineers packaging EEG sensors into sleek headbands that you can order online and wear while you drink your morning coffee. ☕ Both camps have true believers, serious money, and mounting clinical results. And the argument between them isn’t just technical; it’s philosophical.

The core tension is simple to state and maddeningly hard to resolve: signal quality versus accessibility. Invasive devices hear individual neurons firing like a front-row seat at a concert. Non-invasive devices stand outside the venue, pressed against a thick concrete wall, trying to guess what song is playing from the bass they can feel through their shoes. One method is extraordinary precise. The other you can ship to consumers. Neither is obviously correct, which is why 2025 and early 2026 have been so fascinating to watch.

The case for going inside the skull

Let’s be honest about what invasive BCIs can do that nothing else can. 🧠 When you implant a microelectrode array directly into cortical tissue, you get data that non-invasive systems simply cannot replicate. Individual neuron firing rates, millisecond-level timing, rich spatial resolution across hundreds of channels at once — it’s the difference between reading a newspaper and reading smoke signals.

The clearest proof is Neuralink’s ongoing PRIME Study. By mid-2025, the company had implanted its N1 device in nine patients across four countries — the US, Canada, the UK, and the UAE — all of them living with paralysis from spinal cord injury or ALS. The first implant recipient, Noland Arbaugh, has gone from browsing the web by thought to moving physical chess pieces with his mind at the 2026 Robotics Summit in Boston. The second human recipient, Alex Conley, piloted a drone and controlled a robotic arm using only neural signals. These are not lab demonstrations with the subject bolted to a chair. These are people living their lives with an implant and doing things that were flatly impossible before.

What makes Neuralink’s approach technically distinctive:

• 1,024 electrodes on flexible polymer threads thinner than a human hair, threaded into cortex by a robotic surgeon

• A fully wireless, skull-sealed design with no percutaneous cables, which slashes infection risk compared to older Utah Arrays

• An R1 surgical robot that, as of May 2026, can target virtually any brain region — expanding beyond motor cortex to include potential applications in Parkinson’s disease, epilepsy, and treatment-resistant depression

• A closed-loop adaptive system where machine learning models train on individual neural patterns, improving accuracy over weeks

That last point matters more than it sounds. The reason early BCIs had ceiling effects — patients would plateau at a certain level of control — is that decoding algorithms used population-averaged models. Neuralink’s approach personalizes the model to each user’s neurons, and the results show. Arbaugh’s cursor control at 28 months is measurably better than at six months.

Neuralink is not alone in the invasive space. Precision Neuroscience, co-founded by a former Neuralink co-founder, took a different angle: a device it calls Layer 7, an ultra-thin electrode array — essentially a “brain film” — that slips between the skull and the dura rather than piercing brain tissue. In April 2025, Layer 7 received FDA 510(k) clearance for commercial use with implantation durations up to 30 days. Precision’s surgeons demonstrated they can implant the device in under 20 minutes, a time that should make traditional neuromodulation practitioners do a double-take. 🔬

Meanwhile, researchers at China’s Academy of Sciences and Huashan Hospital implanted electrodes — each less than 1% of the diameter of a human hair — into a patient with quadriplegia, enabling him to steer a wheelchair outdoors and command a robotic dog to retrieve food, purely through neural signals. The fact that three major programs on three continents achieved comparable results in the same 12-month window is not a coincidence. It’s a field crossing a threshold.

The uncomfortable truth the invasive camp can’t fully escape: Utah Arrays, the workhorses of clinical BCI research for decades, lose signal from over 60% of their electrodes within the first year as scar tissue encases the implant and muffles recordings. This is the biocompatibility wall that newer flexible designs from Neuralink and Precision are trying to climb over. It’s real progress, but the long-term answer isn’t settled yet.

The non-invasive argument, which is stronger than you think

Here’s what the skull-drilling contingent sometimes forgets: you cannot mass-market brain surgery. 💡 Non-invasive BCIs have a fundamental structural advantage — they can reach everyone, not just patients with life-altering conditions willing to accept surgical risk. The EEG headband on your desk has mediocre signal fidelity compared to a cortical implant, but it also doesn’t require a neurosurgeon, a sterile OR, and a 20-minute cranial incision.

The Johns Hopkins Applied Physics Lab frames the challenge cleanly: today’s highest-impact BCI technologies require invasive implants, while non-surgical methods all suffer from fundamental limitations in spatial resolution, temporal resolution, and signal-to-noise ratio. That’s the honest assessment. But “fundamental limitations” in engineering rarely mean “permanent ceiling.” They usually mean “the next decade’s problem to solve.”

The non-invasive field in 2025 is not sitting still:

• AI-powered signal decoding has dramatically improved EEG interpretation accuracy, squeezing usable intent signals out of noisy scalp recordings that would have been useless five years ago

• Flexible, dry electrode arrays — using nanostructured conductors and novel fabrication — are improving wearability and reducing impedance, the bane of consumer EEG devices

• Multi-modal fusion (combining EEG with fNIRS, fMRI, or accelerometers) is producing richer brain state maps than any single modality alone

• Closed-loop adaptive architectures — the same paradigm making invasive BCIs better — are migrating to non-invasive systems, allowing the device to learn the user’s individual patterns over time

Neurable, a Boston-based company that raised $35 million in a Series A, is now licensing its non-invasive BCI technology to consumer wearable makers. Their platform uses EEG sensors combined with AI signal processing to read cognitive state — attention, fatigue, workload — in real time. That’s not mind control in the cinematic sense, but it’s not nothing either. A productivity app that knows you’ve been zoning out for 12 minutes and gently nudges you back is commercially valuable without requiring you to see a neurosurgeon. 📈

Emotiv has been at this longer than almost anyone, and their research-grade EPOC X headset represents roughly 25% of consumer EEG studies globally. The trade-off is honest and known to everyone in the space: consumer-grade EEG gives you enough signal to distinguish broad mental states but not enough to decode complex intentions. Think “user is engaged vs. bored” not “user wants to turn left.”

The more interesting question — one I’d love to hear your take on in the comments — is whether the gap between non-invasive and invasive signal quality will ever close enough to make consumer BCIs genuinely useful for fine-grained control, or whether that gap is simply a physics problem the scalp will never let us solve.

The middle path: endovascular BCIs and the Synchron bet

Between drilling and headbands lives a genuinely clever third category: endovascular BCIs that reach the brain through blood vessels rather than through the skull or over the scalp. 🩸 It’s the most counterintuitive approach of the three, and possibly the most underrated.

Synchron’s Stentrode device is the leading example. A catheter delivers a mesh of electrodes into the jugular vein; a neurovascular surgeon navigates it up to the superior sagittal sinus, a major draining vein that runs right over the motor cortex. The device lodges there, recording brain signals through the vessel wall without any brain tissue contact. No craniotomy. No drilling. No dura incision.

Synchron’s COMMAND study enrolled six patients with severe bilateral upper-limb paralysis and tracked them for 12 months. Zero serious adverse events related to the brain or vasculature. 100% accurate device deployment in every patient. Participants successfully performed a range of digital tasks using thought-derived commands. Time magazine named the Stentrode one of the best inventions of 2025, and one patient was recently shown controlling an iPad — the first BCI to do so. The company has forged partnerships with both Apple and NVIDIA, which suggests they’re not just thinking about medical devices; they’re thinking about an ecosystem.

The trade-off is exactly what you’d expect: signal quality sits between non-invasive EEG and direct cortical recording. Recording through a vessel wall, you get a sort of averaged field potential — richer than scalp EEG, poorer than a Utah Array sitting in motor cortex. For generating simple digital commands (move cursor left, select, scroll), it’s more than adequate. For decoding complex intended speech or fine finger movements? That’s where the physics get tricky.

What makes Synchron’s case genuinely interesting is the regulatory speed advantage. Vascular procedures for brain conditions are routine; interventional neurologists do them daily to treat strokes. The procedural infrastructure already exists. This gives Synchron a realistic path to broad clinical availability that fully invasive cortical implants, with their requirement for specialized neurosurgical teams, may not match for years. Being less invasive doesn’t just mean less risk for patients — it means faster regulatory clearance and a much larger pool of eligible surgeons who can perform the procedure. That’s a strategic moat, and the backing of Bill Gates and Jeff Bezos doesn’t hurt.

Signal quality is the wrong metric for most applications

Here’s an opinion worth sitting with: the entire “invasive vs. non-invasive” debate is partly a category error. The question shouldn’t be “which gets the best signal?” It should be “which is good enough for the job, at acceptable risk, for the intended user?” 🎯

These categories aren’t racing toward the same finish line. They’re solving fundamentally different problems for fundamentally different populations:

• Fully invasive cortical BCIs (Neuralink, Paradromics, Blackrock) are medical devices for people with severe neurological conditions where surgical risk is justified by potential restoration of lost function

• Endovascular BCIs (Synchron) target a somewhat broader patient population, offering a lower-risk implant for people who need thought-to-device control but may not qualify for or want open-brain surgery

• Non-invasive consumer BCIs (Neurable, Emotiv, Muse) serve a completely different market: able-bodied people interested in cognitive monitoring, gaming, accessibility, or productivity enhancement

The FDA classifies most implantable BCIs as Class III devices, the most stringent category, requiring rigorous premarket approval — appropriate for devices that sit inside your skull. Non-invasive consumer devices mostly face light or no oversight, which has its own implications. A ScienceDirect analysis published in October 2025 raised sharp concerns about this regulatory gap, noting it “opens the door to dystopian scenarios” including insurers using neural risk factors and employers screening for “undesirable” cognitive traits. That’s not science fiction; that’s a policy question we need to answer before the consumer devices get much better.

The non-invasive space also has a privacy problem that the invasive space, paradoxically, handles better. Your Neuralink data lives on a closed wireless system with end-to-end encryption. Your consumer EEG headset probably syncs to a cloud API you agreed to in 11,000 words of terms of service. As of now, only a handful of US states have passed neural data privacy laws, and the regulatory framework for protecting what happens inside your head is, to put it diplomatically, a work in progress. ⚠️

That said, the investment signals are clear. Merge Labs raised $252 million. Chinese startup BrainCo secured $280 million for implantable BCI development. Neuralink announced plans for high-volume N1 production and a near-fully automated surgical procedure by the end of 2025. Paradromics just received FDA approval for its first long-term human trial for a speech-restoration BCI. The field isn’t picking one winner between invasive and non-invasive — it’s splitting into distinct verticals that will coexist for decades.

Who’s actually winning, and what does winning even mean?

I’ll resist the urge to declare a champion, because I don’t think there is one. What I think is happening is a bifurcation of the BCI market into two tracks that will mature at different speeds for different users, with endovascular approaches occupying an interesting bridge position between them. 🔬

The invasive track is further ahead in raw capability and, frankly, more exciting to watch right now. Noland Arbaugh moving chess pieces with his thoughts at a public conference is the kind of demonstration that rewires your sense of what’s possible. Neuralink’s R1 robot targeting Parkinson’s and epilepsy represents a genuine expansion of the clinical case for brain implants beyond paralysis. Phase 3 trials are planned for 2026, with commercial availability for paralysis patients projected as early as 2028.

The non-invasive track is moving more quietly but at a scale the invasive track can’t touch. When Neurable licenses its cognitive-state detection technology to consumer wearables, that technology may reach millions of users — people who will never have brain surgery, never want brain surgery, and shouldn’t need brain surgery just to get adaptive cognitive tools. The numbers will be incomparable. Nine Neuralink patients versus potentially tens of millions of EEG headset users is not a close comparison by volume, even if it’s not a fair comparison by capability.

The question worth asking yourself: if you could have a non-invasive BCI that was 30% as capable as a cortical implant, worn as comfortably as earbuds, and needed no surgical intervention — would you use it? Most people probably would. And if the answer is yes, then “winning” might not belong to the team building the most extraordinary device. It might belong to the team building the most usable one.

Where do you land on this? Are we looking at a future where most people use low-resolution non-invasive BCIs as cognitive tools, while a smaller population with serious medical needs uses high-resolution implants — two parallel futures rather than one convergent one? Drop your take in the comments.

Neurotechnology has a charming habit of sounding like science fiction right up until it lands in your shopping cart. One year, brain-computer interfaces are lab curiosities. The next, you’re wearing a headband that scores your focus while you answer email. 🧠📈⚡

That progress is thrilling. It’s also a little unnerving.

When a device can detect attention, fatigue, stress, or emotional responses, it is not collecting just another stream of biometric data. It is peeking into the machinery that produces your thoughts. That’s a very different category of intimacy. Your step count is personal. Your neural activity is profoundly personal. 🔬🔐💭

The good news is that we still have time to set rules before brain data becomes as casually traded as web cookies. The bad news is that time is short.

So where are the biggest ethical fault lines? I think there are three, and each one is closer than most people realize.

Your thoughts are becoming a product

The first line is simple and unsettling: brain data is turning into a commercial asset. 🧠💰📊

Companies building EEG wearables and neurofeedback tools collect information about attention, relaxation, sleep stages, and emotional patterns. Some of that data is anonymized. Some is not. Even anonymized data tends to become less anonymous over time, which is one of technology’s least amusing recurring jokes.

The Organisation for Economic Co-operation and Development and UNESCO’s Recommendation on the Ethics of Artificial Intelligence both stress that biometric and cognitive data need special protection. They are right.

What makes neural data uniquely sensitive? 🧬🔍🛡️

Attention patterns may reveal mental health states Emotional responses may expose fears and preferences Sleep signals can indicate cognitive decline or burnout Long-term trends may become health indicators before symptoms appear

Would you allow an insurer to infer depression risk from your sleep headband? Would you let an advertiser know exactly when your attention spikes? Those questions are no longer hypothetical.

I think companies should follow a few hard rules:

No sale of raw brain data Clear opt-in consent Easy deletion tools Short retention periods * Independent audits

If a neurotech company cannot explain its data policy in plain English, that is not a minor oversight. It is a warning label. 🚨🧠📄

Employers will be tempted to measure your mind

The second line is workplace surveillance. This one worries me more than most speculative AI scenarios because the incentive is obvious and immediate. 🏢🧠⏱️

Imagine a headset that estimates focus and flags fatigue in real time. That sounds useful in aviation, surgery, and other safety-sensitive jobs. It also sounds like something a call center manager would love a little too much.

According to Wikipedia’s article on workplace surveillance, monitoring technologies tend to expand beyond their original purpose. History is not subtle on this point.

Potential misuse includes:

Productivity scoring based on brain activity Hiring filters that infer attention traits Fatigue alerts used to penalize workers Emotional monitoring during customer interactions

To be fair, some applications are legitimate. Detecting drowsiness in truck drivers may save lives. 🚚⚠️🧠 But “helpful safety tool” can morph into “mandatory mind tracker” faster than HR can schedule a webinar.

What should happen before adoption?

Ban mandatory consumer neurotech at work Require collective bargaining where applicable Limit use to narrowly defined safety cases Prohibit employment decisions based on neural metrics

Would you wear a focus-monitoring headset if your bonus depended on it? Most people already know the answer.

Courts and governments may want access

The third line is legal and governmental access to neural data. Once information exists, someone eventually asks for it. Usually with paperwork. ⚖️📁🧠

In 2024, the state of Colorado amended its privacy law to explicitly protect neural data, one of the first laws in the world to do so. That is a smart start, not a finished job.

Without stronger rules, neural records may be sought in:

Civil lawsuits Criminal investigations Immigration proceedings Insurance disputes

This creates a chilling possibility: your own brain signals becoming evidence against you or used to infer states of mind you never intended to reveal.

The Neurorights Foundation argues that mental privacy should be treated as a basic human right. I agree. It sounds dramatic until you realize that the alternative is letting cognitive data fall under rules built for loyalty cards and browser histories. 🛒💭🔐

Governments should establish:

Strict warrant requirements Limits on admissibility Special protections for inferred mental states International standards for neural privacy

Because once courts normalize access, reversing course will be painfully difficult.

We need neurorights before neurotech becomes ordinary

The phrase neurorights may sound academic, but the idea is straightforward: your thoughts should belong to you. 🧠🛡️🌍

For a deeper look, NeurotechMag readers may enjoy our related coverage on consumer wearables and brain-computer interfaces at NeurotechMag. The conversation is moving quickly, and it needs more than breathless gadget reviews.

The core principles are refreshingly practical:

Mental privacy Cognitive liberty Protection from algorithmic bias Control over personal neural data

None of this requires halting innovation. It requires guardrails, the same way seatbelts did not ruin cars.

Neurotechnology may help millions improve sleep, communication, and treatment for neurological disorders. That is worth celebrating. 🎉🧠🔬 But if we fail to define ethical limits now, convenience and commercial pressure will define them for us.

So before your brain becomes the most valuable dataset you generate, ask a blunt question: who should have access to your thoughts, and under what conditions?

Your brain is chatty. It crackles with electrical signals all day, muttering about emails, caffeine, deadlines, and whether you really need that third espresso. ☕🧠⚡ For years, tapping into those signals meant a lab, a tangle of wires, and a graduate student whispering “please don’t move.”

Not anymore.

In 2026, non-invasive neurotech is finally shedding its science-fair vibe. The best devices are sleeker, smarter, and less interested in impressing investors with jargon. They want to help you sleep better, focus longer, and maybe understand your own mind a little more clearly. That’s a big promise. Sometimes too big.

Still, a handful of wearables look genuinely interesting. Not because they read your thoughts, they absolutely do not, but because they gather real brain and body data and turn it into useful feedback. 🧬📈🎧

If you’re curious where consumer brain-computer interfaces are heading, these are the devices I think deserve a spot on your radar.

The productivity headset that means business

The most ambitious device in this category is Neurosity Crown. It looks like a futuristic tiara designed by someone who drinks cold brew and writes Rust code. 👑💻⚡

Unlike meditation gadgets that politely tell you to breathe, Crown is built for people who want raw EEG data, developer tools, and integrations with AI systems like ChatGPT and Claude. According to Neurosity, the headset uses 8 EEG channels and performs signal processing directly on the device, which is exactly the kind of engineering detail that makes neurotech nerds grin like kids in a candy store. ([Neurosity][1])

What makes it interesting? 🧠🚀📊

Real-time brainwave monitoring during work sessions Focus tracking and adaptive audio cues Developer SDKs for custom applications Native AI integrations, which sounds a little absurd and a little brilliant

This is not a casual purchase. At around $1,499, it is expensive enough to provoke a raised eyebrow and perhaps a call from your accountant. But if you are serious about neurofeedback or BCI development, it is one of the few devices that feels like a real platform instead of a wellness toy.

Want to build your own brain-powered apps? Crown is probably the most intriguing consumer headset on the market.

The sleep headband that knows what your brain did last night

If Crown is for coders, Muse S Athena is for people who wake up and immediately ask, “How much deep sleep did I get?” 😴🌙🧠

Muse has been the household name in consumer EEG for years, and Athena is its most advanced model yet. It combines EEG and fNIRS, a light-based technique that measures blood oxygen changes in the brain. That’s unusually sophisticated for a device wrapped in soft fabric. Wikipedia’s fNIRS overview is worth a look if you enjoy reading about photons before breakfast.

Why Athena stands out ✨📉💤

EEG-based sleep staging Meditation and neurofeedback fNIRS brain oxygen tracking No required subscription for core functionality

Users on Reddit report that its sleep estimates often feel more believable than wrist-based trackers because EEG measures actual brain activity rather than making educated guesses from heart rate and movement. ([Biohacker Atlas][2])

Let’s be honest, if your ring says you slept like a squirrel in a windstorm but your EEG says you were out cold, I would trust the device reading your brain.

Would you wear a headband every night? That’s the real question.

The brainband that wants to fix your sleep

FRENZ Brainband from Earable Neuroscience is one of the most interesting underdogs in neurotech. It combines EEG sensors with AI-generated audio to help guide sleep and improve focus. At CES 2026, the company unveiled a high-end SuperBrain Edition, which sounds either incredibly cool or slightly ridiculous, depending on your tolerance for luxury branding. 🛌🎧🧠 ([PR Newswire][3])

What it offers:

Real-time EEG monitoring Personalized sound therapy Sleep and mental recovery support A design that looks less “medical experiment,” more “premium travel accessory”

I like this category because it tackles a practical problem. Most people do not want to control a cursor with their thoughts. They want to fall asleep faster and stop waking up at 3:17 a.m. thinking about invoices.

That’s a much bigger market.

The devices that may define the next wave

Not every notable neurotech wearable is on store shelves yet. Some are prototypes, some are quietly maturing, and some may vanish before next year’s CES. That’s normal. Hardware is hard. 😅🔬📦

Names worth watching include:

LumiMind and its LumiSleep headband Neurable, which is shifting toward licensing its technology to other brands * NeuroTx and its WillSleep device using vagus nerve stimulation

These products suggest a broader trend: neurotech is becoming less about flashy demos and more about everyday use cases.

The likely winners will do a few things well:

Feel comfortable enough to wear regularly Deliver understandable insights Avoid burying features behind subscriptions Solve a problem people already care about

That last point matters most. Nobody buys a headset because it has eight electrodes. They buy it because they want to sleep, focus, or feel better.

So, is consumer neurotech finally ready?

I think it is getting close. Not because these devices can read your thoughts, they can’t, but because they are becoming useful enough to fit into real routines. 🧠📅⚡

There are still caveats.

Signal quality depends heavily on fit Scientific claims vary from solid to squishy * Prices range from reasonable to “I should probably discuss this with my spouse”

Yet the progress is hard to ignore. A few years ago, consumer neurotech felt like a collection of expensive science projects. In 2026, it feels more like an emerging product category.

For deeper context, Wikipedia’s brain-computer interface overview is an excellent starting point, and NeurotechMag’s own coverage of consumer BCIs will likely expand quickly as these devices mature.

So here’s the real question. If a comfortable wearable could show exactly when your mind is focused, calm, or drifting, would you want to know? 🧠🔍✨

Here’s a thought that might ruin your morning routine in the best possible way: you’re probably already a neurotech user. Not in the “sci-fi implant” sense that Neuralink headlines love to conjure, but in the quieter, more interesting way — the kind where the device on your wrist or tucked in your ears is doing something to your nervous system that its own marketing barely bothers to mention.

Neurotechnology, at its core, is any device that reads from or writes to the nervous system. That definition is broader than most people realize, and it means a surprising number of gadgets you already own qualify. The global neurotech market is on track to grow from roughly $15–17 billion in 2025 to over $47 billion by 2035, according to market projections cited by researchers tracking the sector’s expansion — and a big chunk of that growth is already sitting on consumer shelves, wrapped in lifestyle branding that says “wellness” or “audio” or “recovery” rather than anything that sounds remotely like brain science.

This isn’t a list of speculative future products. Every single device below is real, available, and probably more interesting than the box it came in suggests. And if you’ve been curious about whether neurotech is actually close to you yet — the answer, it turns out, was yes all along. You can also check what the broader tipping point for this industry looks like to understand why this moment matters.

1. The Oura Ring — a sleep tracker that reads your nervous system 🧠

The Oura Ring markets itself as a sleep and wellness tracker. Small, titanium, looks like a stylish band. But what it actually does — continuously, every night you wear it — is measure the autonomic nervous system in ways that would have required a clinical lab setup a decade ago.

Inside that unassuming ring sit infrared photoplethysmography sensors, a thermistor, and a three-axis accelerometer. Together, they reconstruct your heart rate variability (HRV): the millisecond-level fluctuation between heartbeats that reflects how your ANS is balancing its sympathetic (”fight or flight”) and parasympathetic (”rest and digest”) branches. HRV is one of the most studied proxies for brain-body regulation in neuroscience, used in research on stress, cognitive load, and recovery.

A peer-reviewed study published in Sensors and conducted by researchers at Brigham and Women’s Hospital found the Oura Ring was the most accurate consumer sleep tracker in four-stage sleep classification compared to polysomnography, outperforming both the Apple Watch and Fitbit Sense. Specifically:

• The ring achieved 79% agreement with polysomnography in four-stage sleep classification

• It was 5% more accurate than Apple Watch and 10% more accurate than Fitbit on the same metric

• It was the only device that did not significantly overestimate or underestimate any of the four sleep stages

Polysomnography, by the way, is the gold-standard sleep test — a full-night study with electrodes monitoring brain waves, eye movements, and muscle activity. The fact that a $300 ring approaches its accuracy is, frankly, remarkable. The catch, of course, is that the ring is not FDA-cleared as a medical device and cannot diagnose anything. But it’s reading your nervous system every single night. 🔬

What does this mean for you? If you wake up and check your “readiness score,” you’re looking at an algorithmic summary of how your autonomic nervous system performed while you slept. That’s neurotech. It just doesn’t say so on the box.

2. Apple Watch — your cardiac neural monitor that also tells time ⌚

The Apple Watch has been the most popular wrist-based activity tracker for years, with roughly 58% of all wrist-worn health trackers sold in the U.S. being Apple Watches, according to research cited in the Brigham and Women’s sleep validation study. Most people wear it to count steps and check notifications. They may not fully appreciate what they’re strapping to their wrist.

Apple’s ECG app, available since Series 4, uses a single-lead electrocardiogram chip to record the electrical activity of your heart. This is direct biopotential measurement — the same fundamental technology used in hospital cardiac monitoring rooms, miniaturized to a watchband. When Apple then added atrial fibrillation detection and, as of late 2024, sleep apnea monitoring via its breathing disturbance algorithm, the device crossed into genuinely clinical territory. The FDA cleared each of these features separately.

Here’s what the device is actually doing to earn those clearances:

• Detecting irregular atrial rhythm using machine learning trained on millions of ECGs

• Estimating autonomic nervous system tone through overnight HRV measurement

• Flagging respiratory disruptions during sleep that correlate with apneic events

• Measuring blood oxygen saturation (SpO2), which reflects both pulmonary and neural oxygen delivery

The sleep apnea feature is particularly significant from a neurological standpoint. Sleep apnea is not just a breathing problem — repeated oxygen deprivation during sleep has documented effects on hippocampal volume, executive function, and long-term dementia risk. A watch that can flag these events in someone who had no idea they were happening is doing something genuinely important for brain health. 🧬

Is it a brain-computer interface? No. But it reads biopotential signals from your body’s nervous system and translates them into clinical health alerts. The line between “consumer wearable” and “medical-grade neurotech” is thinner here than Apple’s marketing department would probably prefer to admit.

3. Neurable MW75 Neuro headphones — the BCI you thought was just good audio 🎧

Now we get into territory that should genuinely surprise you. The Neurable MW75 Neuro headphones look, from the outside, like a pair of premium over-ear headphones — the kind you might buy to block out a noisy open office or soundtrack a long flight. They are, in fact, a brain-computer interface you wear on your head while listening to music.

In partnership with audiophile brand Master & Dynamic, Neurable embedded 12-channel dry EEG electrodes into the earcup fabric of the MW75. These sensors pick up electrical activity from your scalp — the same signals a clinical EEG machine records — with a bandwidth of 0 to 131 Hz and true DC coupling. While you work, the headphones monitor your cognitive state in real time.

The MW75 Neuro’s companion app:

• Tracks focus levels over the course of your work session

• Detects cognitive fatigue and attention drift using machine learning trained on EEG patterns

• Can silence notifications automatically when you enter deep focus states

• Logs your brain’s daily performance trends over weeks

The fact that Neurable — a Boston-based BCI company — launched this not as a research device but as a commercial product at $399 matters enormously. It means that the consumer BCI era isn’t just approaching; it’s already here, hanging on the headphone hooks of people who think they bought a nice pair of cans. This is exactly the kind of consumer-ready BCI shift we’ve been tracking closely.

Neurable CEO Ramses Alcaide frames this as “the beginning of BCI-enabled technology for all.” I think that’s probably right — and I think most people who bought these headphones have no idea they’re early BCI adopters. 🔬

4. AirPods Pro — FDA-cleared medical devices in your ears right now 👂

In September 2024, the FDA did something it had never done before: it authorized the first over-the-counter hearing aid software for a consumer product. The product was the Apple AirPods Pro 2. The AirPods Pro 3, launched in September 2025, carries the same FDA-cleared hearing aid capabilities forward.

Let that land for a moment. The earbuds that hundreds of millions of people use to listen to podcasts and take calls are now also, officially, FDA-cleared medical devices for people with mild to moderate hearing loss. Apple applied via the de novo premarket review pathway — the same route used for novel devices without existing substantial equivalents. The FDA had never cleared software-only hearing aids before.

What the hearing aid feature actually does:

• Runs a personalized hearing test through the iPhone, calibrating to the user’s specific hearing profile

• Applies computational audio processing to boost speech frequencies the user struggles with

• Uses machine learning to separate and clarify speech in noisy environments

• Adjusts continuously and in real time, adapting to each acoustic environment

Hearing is fundamentally a neurological process. The cochlea converts physical sound waves into electrical signals that the auditory nerve carries to the brain’s auditory cortex. When hearing is impaired and a device compensates for that impairment by modifying the signal before it reaches the ear, that’s neurotechnology. Full stop. The FDA’s own announcement uses the word “hearing aid” without qualification.

An estimated 37.5 million American adults have some degree of hearing loss, according to the National Institute on Deafness and Other Communication Disorders. The vast majority go untreated — partly due to stigma, partly due to cost. AirPods Pro have just made FDA-cleared hearing assistance so frictionless that most people will never even think of it as a medical intervention. That’s probably how it should work. 🧠

Have you ever wondered what else your earbuds are doing besides playing audio? This might be the moment to look into it.

5. Vagus nerve stimulators — stress relief devices doing direct neuromodulation 🌿

The vagus nerve is the longest cranial nerve in the body, a wandering cable running from the brainstem through the chest and into the abdomen, regulating heart rate, digestion, inflammation, and mood. Stimulating it electrically has been an approved treatment for epilepsy and depression since the late 1990s — but those were implanted devices requiring surgery. The consumer versions came much later and much quieter.

Devices like the Pulsetto and Truvaga Plus deliver transcutaneous vagus nerve stimulation (tVNS) by placing electrodes on the neck or behind the ear, where the nerve runs close to the surface. The Truvaga Plus, made by electroCore — the same company that makes the gammaCore, which is FDA-cleared for migraine and cluster headache treatment — operates at around 25 Hz, aligned with studied clinical parameters. Neither consumer device is FDA-cleared as a medical product, but the underlying mechanism is not in dispute: they are directly stimulating the vagus nerve with electrical current.

The independent testing site Innerbody, which tested multiple devices head-to-head, found that Truvaga Plus produced “the fastest and most noticeable effects for focus, stress, and sleep quality” compared to competing products. Pulsetto, a European brand, holds FCC certification and has been adopted by hundreds of thousands of users seeking a drug-free approach to anxiety and sleep support.

What users experience:

• A mild buzzing or tingling sensation at the stimulation site

• Reported reductions in subjective stress, sometimes within minutes

• Improved sleep onset over weeks of daily use

• Shifts in HRV that reflect increased parasympathetic activity

The critical thing to understand is the mechanism. These devices are not delivering “gentle vibrations” or “relaxing pulses” in the way that a massage chair might. They are applying electrical current to a cranial nerve that directly modulates brain stem activity, including the locus coeruleus — the brain’s primary norepinephrine center. That’s a specific neurological intervention. The wellness industry just hasn’t given it that name. ⚡

6. TENS and EMS devices — the gym gadgets that work by hijacking nerves 💪

Walk into any sports performance shop, Amazon warehouse, or physio clinic and you’ll find them: TENS (transcutaneous electrical nerve stimulation) and EMS (electrical muscle stimulation) units, sold as muscle recovery and pain relief tools. Therabody’s PowerDot 2.0, Compex’s range of devices — these are in gym bags across the world.

What they are, technically, is electrical neurostimulators. They work by delivering electrical pulses through electrode pads placed on the skin, targeting sensory and motor nerves directly:

• TENS works by stimulating sensory nerve fibers, which activates spinal gate-control mechanisms to block pain signals — a concept rooted directly in neuroscience first described by Melzack and Wall in 1965

• EMS/NMES (neuromuscular electrical stimulation) bypasses voluntary motor control and forces muscle contractions by stimulating the motor nerves innervating a muscle group

• The two are often combined in the same device, addressing both pain and activation

Before EMS became popular for sports recovery, it was a clinical tool developed in the 1960s to prevent muscle atrophy in patients with nerve injuries and post-orthopedic surgery. The jump to consumer sports products changed the branding entirely but not the underlying mechanism. When you slap those pads on your quads after a long run and hit “recovery mode,” you’re using technology derived from clinical neuroscience. 🔬

PowerDot, now under the Therabody umbrella, integrates with fitness apps to tailor stimulation programs to your specific workout history — an early version of the closed-loop neuromodulation that researchers are building toward in clinical settings. The fact that you’re also listening to a podcast while it runs doesn’t make it any less neuro.

I’ll be honest: I think most people who own one of these devices would not describe themselves as neurotech users. They probably should.

7. Muse headband — a real EEG machine sold as a meditation coach 🧘

The Muse headband has been on the market since 2014. It’s a soft headband with embedded EEG sensors on the forehead and behind the ears, connected to an app that translates your brain wave activity into real-time audio feedback during meditation. When your brain is calm, you hear birdsong. When attention wanders, the app plays the sound of a storm picking up.

This is neurofeedback — a clinical technique with roots going back to the 1960s, where practitioners use real-time EEG data to train people to shift their own brain states. The Muse S model added the ability to track sleep stages directly through EEG, and researchers have used it in published studies. It is not a research-grade clinical device, but it is measuring actual brain electrical activity — delta waves, theta waves, alpha waves — and using that data to shape a behavioral feedback loop.

Key things the Muse tracks using real EEG signals:

• Alpha wave activity (8–12 Hz), associated with relaxed, unfocused attention

• Theta wave patterns (4–8 Hz), which increase during deep meditation and light sleep

• Delta activity (0.5–4 Hz) during deep sleep stages

• Gamma oscillations (30+ Hz) during periods of heightened cognitive engagement

The Muse Sleep app specifically uses this data to calculate sleep stages in a way comparable to how clinical EEG-based systems approach it. For anyone interested in what’s happening in their brain during meditation, this is genuinely fascinating — and the science of brain stimulation and cognitive change is a useful backdrop for understanding what neurofeedback is actually trying to do.

The honest caveat: consumer EEG accuracy drops off compared to clinical systems with gel electrodes and trained technicians. But the signals are real. The feedback loop is real. And for many users, the shift in self-awareness about their own mental states is real too. 🧬

The Muse is probably the most transparent neurotech device on this list — it’s genuinely trying to tell you it’s reading your brain. Somehow, even so, most people who’ve heard of it still think of it as a meditation gadget rather than what it technically is: a portable EEG system with a built-in neurofeedback protocol.

The bigger picture — neurotech without the label ⚡

What all seven of these devices have in common isn’t a technology — it’s a category error in how they’re sold. Consumer products land in categories like “wellness wearable,” “premium audio,” “recovery tool,” or “mindfulness aid.” Those categories are not wrong, exactly, but they obscure the underlying science in a way that matters.

It matters because:

• Understanding what a device actually does shapes how you use it and what you expect from it

• The data these devices generate about your nervous system is genuinely sensitive, and you probably want to know what’s happening to it

• Neural data privacy is one of the most underexplored issues in consumer tech, and it’s only going to become more relevant as these devices get more capable

• The “wellness” framing sometimes creates inflated expectations that the actual mechanism can’t meet — and sometimes undersells capabilities that are legitimately impressive

The neurotechnology sector surpassed $1.3 billion in disclosed funding in 2025 alone, according to data tracked by researchers in the space. Investors are betting at that scale because the hardware is real, the science is solid, and the consumer adoption is already well underway — in your gym bag, on your finger, and in your ears.

The question isn’t whether neurotech is coming to your life. It’s already there. The question is whether you want to actually understand what the devices around you are doing to your nervous system — and what that understanding might change about how you use them.

Which of these seven devices surprised you the most? Drop your reaction in the comments — I’m curious whether it’s the headphones, the earbuds, or something else entirely that reframes how you think about what you already own. 👇

There is a specific kind of headache that follows you around if you try to stay genuinely informed about neurotechnology. It starts with a headline: “Scientists restore vision in blind patients using brain implant.” You click through. The article is breathless. The company’s press release is even more breathless. And somewhere in the fifth paragraph, if you read that far, you find out the study involved four participants, lasted six weeks, and the company has not yet begun a regulated clinical trial. The headline was technically accurate. The impression it created was almost entirely wrong.

This is the core problem with following neurotech news right now. The field is genuinely moving fast — the MIT Technology Review named BCIs one of its 10 breakthrough technologies of 2025 — but it is also surrounded by a fog of founder claims, venture-funded optimism, and science journalists who don’t always know the difference between an Investigational Device Exemption and an FDA approval. Those are very different things. One means you can run an experiment. The other means you have a product. 🧠

In 2024, researchers published over 14,000 peer-reviewed papers with “brain-computer interface” in the title or abstract. That’s roughly 38 papers per day, according to Neurosity’s 2026 newsletter guide. Nobody reads 38 papers a day. Nobody should try. But if you care about where this technology is actually going, you need a practical system for separating signal from noise — and right now, most neurotech coverage makes that unnecessarily hard. Here’s how to build that system. 🔬

Know the difference between a press release and a paper

The single most reliable filter in neurotech media literacy is asking one question first: did this claim survive peer review? A press release from a company CEO is not evidence. A YouTube demo is not evidence. An interview on a podcast, however compelling, is not evidence. What counts is a peer-reviewed paper in a reputable journal, with a full methods section, independent authorship, and reproducible data.

This sounds obvious until you realize how rarely the distinction gets made in coverage of companies like Neuralink. University of Pennsylvania professor Anna Wexler put it directly in a 2024 STAT News piece: Neuralink has published exactly one peer-reviewed article, and it appeared in a journal unrelated to neural engineering, listing authors as “Elon Musk and Neuralink” in a way that “deviates from the norms of scientific publishing.” Meanwhile, the company has disclosed most of its progress via social media, livestreams, and carefully staged demos. That’s their right. It’s not science. 📋

A few practical benchmarks to apply to any neurotech claim:

• Press release only: Treat it as a hypothesis, not a finding. Companies have financial incentives to announce progress. Read with appropriate skepticism.

• Preprint (not yet peer-reviewed): More rigorous than a press release, but the methodology hasn’t been independently scrutinized. Worth tracking, not yet worth citing.

• Peer-reviewed in a relevant journal (like Nature Electronics, Nature Neuroscience, the Journal of Neural Engineering, or Science Translational Medicine): Now you have something. Check the sample size, the duration, and whether the data came from an independent lab or the company itself.

• Independent replication: This is the gold standard that the BCI field almost never reaches yet, because the field is too young. Note when results have been reproduced across multiple labs.

Dr. Laura Cabrera, a neuroethics researcher at Penn State, has described the pattern bluntly: tech company founders are “showmen” who “make these hyperbolic claims, and I think that’s dangerous, because I think people sometimes believe it blindly.” 💡 That’s not cynicism — it’s a description of an incentive structure. Knowing the incentive structure helps you read past it.

Learn the regulatory ladder

Most neurotech coverage treats “FDA approved,” “FDA cleared,” “FDA Breakthrough Device designation,” and “IDE approved” as roughly synonymous. They are not, at all, and conflating them produces genuinely misleading impressions of where a technology stands.

Here is what the terms actually mean, in plain English:

• IDE (Investigational Device Exemption): The FDA gives you permission to run a clinical experiment on humans. This is where Neuralink’s PRIME Study lives. It does not mean the device is approved for sale or clinical use outside the trial.

• Breakthrough Device designation: The FDA agrees to accelerate its review process for your device because it addresses a serious condition. Neuralink’s Blindsight implant received this in June 2025. It is not an approval; it’s a fast lane toward one.

• FDA clearance (510k): The device has been shown to be substantially equivalent to an already-cleared device. Precision Neuroscience’s Layer 7 electrode array has this for temporary surgical mapping. Again, not approval for chronic implantation.

• FDA Premarket Approval (PMA): Full approval for commercial sale. As of early 2026, no implantable BCI has achieved this.

The Wikipedia overview of brain-computer interfaces is a reasonable starting point for understanding the historical arc, but for current regulatory status, the most reliable primary source is ClinicalTrials.gov, where all regulated human trials must register. If a company claims human trials are underway but has no registration on ClinicalTrials.gov, that’s a serious red flag. 🚨

A scan of the real trial registry as of early 2026 shows that the PRIME Study (Neuralink), Connect-One (Paradromics), and various Synchron Stentrode trials are all properly registered and documented there. You can read the actual endpoints, enrollment criteria, and safety disclosures yourself. This is far more informative than a press release.

Build a source stack that has actual range

The problem with most people’s neurotech source lists is that they’re either all primary literature (you drown in jargon) or all tech journalism (you drown in hype). A useful source stack has range: some primary, some interpreted, some critical.

For primary literature and rigorous science journalism, the best sources currently available are:

• The Transmitter is probably the most important single addition to your reading list. It’s a dedicated neuroscience journalism outlet whose pieces are written by journalists and scientists, with real methodology transparency. Its weekly updates cover BCI research at a level of depth that general tech press rarely reaches.

• Nature Neuroscience email alerts — configure them by topic. The papers that survive Nature‘s peer review represent genuinely high-quality science, even if you need some neuroscience background to read them.

• Neurotech Reports covers the industry side, with annual market analyses and conference reporting from events like the Neurotech Leaders Forum. Less about the science, more about companies and regulation.

• **MIT Technology Review’s biotech coverage** is consistently the best general-audience reporting on what the trial data actually says, with appropriate skepticism toward founder claims.

• IEEE Brain initiative updates for engineering-side advances, especially when new chip architectures or signal processing approaches are involved.

What you probably don’t need:

• Most general tech blogs, which recycle press releases with slightly different headlines

• Elon Musk’s X account as a source for Neuralink progress, for obvious reasons

• Market size forecasts from research firms as evidence of scientific progress (they are not the same thing at all)

Do you already use any of these sources? And is there a specific category of neurotech coverage you find consistently over-hyped or under-reported? 🎯

How to read a clinical trial announcement

When a company announces a new trial or a milestone result, there’s a short checklist that separates useful information from noise. Running through it takes about two minutes and dramatically improves your calibration.

Start with the trial phase. Early feasibility studies (like most current BCI trials) involve small numbers of participants — sometimes as few as two — and are designed to establish basic safety, not prove efficacy. They are not product launches. Pivotal trials, the kind that produce data regulators actually use to make approval decisions, require much larger cohorts and haven’t yet happened for implantable BCIs.

Check who authored the result. A company reporting its own trial outcome is different from an independent academic team assessing the same data. Raj Rao, co-director of the Center for Neurotechnology at the University of Washington, has made the point that “the BCI companies of today are standing on the shoulders of academic giants who have been developing BCIs for decades.” Academic labs produce independently verified results; company-reported outcomes don’t always.

Look for specific metrics, not vague superlatives. “Breakthrough performance” means nothing. 8.0 bits per second in grid-based cursor tasks, the figure Neuralink has reported for its first participant, is an actual number you can compare against prior work and against the approximately 10 bits per second that able-bodied mouse users achieve. Specific numbers are honest; vague adjectives are not. 📊

Ask what the comparison condition is. A result that says “patients showed improvement” without specifying compared to what is nearly useless. Compared to their own pre-implant baseline? Compared to the best alternative device? Compared to no intervention? The comparison defines what the result actually means.

Finally, note whether adverse events are reported. Ethical trial reporting includes safety data. A result that only discusses the positive outcomes and never mentions adverse events is not full disclosure — it’s marketing dressed as science. The 2025 annual neurotech review at TechLifeSci is a good model for what balanced industry coverage looks like: it names companies, cites specific endpoints, and acknowledges both advances and limitations within the same article. ⚡

What you can actually trust right now

After running all that filtering, what does legitimate neurotech progress actually look like in 2026? Here’s the honest accounting of what the peer-reviewed evidence and properly reported trial data support:

• Cursor control via motor cortex implants in paralyzed patients is real, durable, and genuinely useful. Noland Arbaugh using his Neuralink device for 10 hours a day is not a press release claim — it’s documented, observable, and consistent with decades of academic BCI research.

• Speech restoration via neural decoding in ALS patients is happening, and it’s not just Neuralink — the Paradromics Connexus system received FDA IDE approval in 2025 specifically targeting speech restoration as a primary endpoint.

• High-density subdural chips like BISC from Columbia and Stanford represent genuine engineering advances, published in Nature Electronics in December 2025 with full data, a GitHub repository, and an archived dataset.

• Non-invasive consumer devices claiming to enhance focus or decode emotions are, with very few exceptions, not backed by anything close to the evidence standards of invasive BCI trials. The gap in rigor between a clinical implant trial and an EEG headset sold on a website is immense.

• Enhancement for healthy users remains speculative at best. The entire current evidence base for implantable BCIs comes from patients with severe neurological conditions. Extrapolating from that to enhancement applications, as some founders do frequently, is not supported by any available data.

The single most actionable thing you can do right now, if you want to follow this field seriously: bookmark ClinicalTrials.gov and run a search for “brain-computer interface” once a month. The raw trial registrations tell you more about what’s actually happening in BCI research than any week’s worth of press coverage. Which specific trial — active right now — are you most curious to track over the next 18 months?

When Noland Arbaugh revealed himself as the first human to receive a Neuralink implant, the clip that went viral was him playing chess with his thoughts. That one image — a paralyzed man moving pieces on a board purely through brain signals — pretty much consumed the media cycle for a week. What it didn’t show was what happened three months later, when a significant portion of the device’s ultrafine electrode threads quietly retracted from his brain tissue, degrading his control and leaving the engineers scrambling. Arbaugh chose not to say anything publicly at the time. He thought it would be “extremely rash” to go public before Neuralink had a chance to fix it.

He was right to wait. They fixed it, mostly — by rewriting the signal detection algorithm to become more sensitive to the remaining electrodes. But the episode tells you something the highlight reel doesn’t: this technology is genuinely experimental, living in the gap between medical device and work-in-progress, and the people using it are navigating that gap in real time, every single day.

By early 2026, Neuralink has implanted roughly 21 participants, referred to internally as “Neuralnauts,” across its PRIME Study and newer VOICE trial, covering people with cervical spinal cord injuries and ALS. The trials now run in the United States, Canada, the United Kingdom, and the UAE. We know the names of a handful of those participants, and their stories are worth telling properly — not as miracles, not as cautionary tales, but as lives being rebuilt with one of the most unusual tools in medical history. 💡

What Noland Arbaugh’s days actually look like

Arbaugh is 31, quadriplegic since 2016 when a swimming accident dislocated two of his vertebrae, and he now uses his Neuralink implant for roughly 10 hours a day. That number is worth sitting with. This isn’t a lab device he activates for a two-hour research session. He uses it to browse the internet, read books, write emails, play video games, and, as of fall 2025, take a full semester load of chemistry, biology, and pre-calculus courses. He’s earning top grades, which he credits directly to the chip.

Before the implant, by his own account, he couldn’t be left alone for 30 minutes. The contrast since then has been so stark that he’s begun building a professional speaking career. In September 2025, he was a paid speaker at Fortune’s Brainstorm Tech conference in Park City, Utah. He has described that sentence — “I was a paid speaker at a conference” — as something that seemed literally impossible two years ago. 🎤

But the daily reality has friction in it that the conference appearances don’t capture. A few specifics that Fortune reported after spending time with him 18 months post-surgery:

• The N1 implant runs on a battery that needs charging approximately every five hours. Neuralink heat-treats the charging coil into some of his hats, so he charges by literally wearing a hat.

• Recalibrating the “model” — the software that maps his imagined physical movements to cursor movements — degrades over hours and days. During a November 2024 livestream, he mentioned spending up to 45 minutes redoing a calibration task before getting usable control.

• His cursor speed in grid-based tasks has measured around 8 to 9 bits per second, compared to the approximately 10 bits per second that the median able-bodied mouse user achieves. That gap sounds small, but it matters for usability.

• He has named his implant “Eve,” as Wikipedia documents in his public updates, which says something about how personal this relationship has become.

The thread retraction setback was real, and it shaped how Neuralink approached subsequent implants. The company modified algorithms, but also learned from the engineering failure in ways that directly affected patient two. 🔧

Alex Conley is flying drones. With his brain.

Alex Conley, who received the second implant in July 2024 after a 2021 car rollover left him paralyzed from the waist down, has become one of the more remarkable data points in BCI history. In late 2025, he confirmed publicly that he is using the Neuralink device to control a robotic arm and to pilot a drone. With his thoughts. I’ll admit I had to re-read that sentence the first time I encountered it.

Conley’s background is in welding and fabrication — he worked in mechanics before the accident. The BCI has pulled him back toward that world in a way that a purely digital device couldn’t have. Using Neuralink-enabled CAD software, he’s returned to designing tools and parts on a computer. He and the Neuralink engineering team collaborated on a custom mount for his charging system; he designed the part, the team sent it to a printer in Phoenix, and he had it the next day. That workflow — paralyzed man designs physical hardware he cannot touch, engineers manufacture it overnight — is not something you can describe without feeling the weight of it. 🦾

Conley’s experience also avoided the thread retraction issue that plagued Arbaugh’s first months. That suggests Neuralink incorporated learnings between the first and second implants quickly, which matters for what the PRIME Study is actually producing: real iterative data on how to make the next implant better.

What Conley can do now versus a typical BCI recipient from even five years ago:

• Drone piloting via neural signals, translating imagined movement into real-time directional control

• Robotic arm operation for daily physical tasks, allowing interaction with a world that otherwise requires hands

• CAD design on a computer using cursor control via thought, enabling professional work he thought was permanently behind him

• Posting to social media independently, which may sound trivial until you consider he couldn’t operate a phone without assistance before

Bradford Smith found his voice, literally

The third Neuralink patient — Bradford Smith, who has non-verbal ALS — represents the application that may matter most in the long run. ALS is a disease that leaves the mind intact while systematically dismantling the body’s ability to communicate it to the world. Smith can no longer speak. His motor neurons are dying. But he can still intend to speak, and the Neuralink device reads those intentions.

What makes his case different from Arbaugh’s or Conley’s is the AI layer on top of it. Smith’s speech output uses an AI model trained on recordings of his voice from before he lost the ability to speak. When he types using brain-controlled cursor movement and a virtual keyboard, the system synthesizes his words in his own voice, not a generic text-to-speech voice. As Neuralink co-founder DJ Seo described it when discussing the moment Smith played Mario Kart with his children again: “That moment was incredible.” 🧬

Smith’s daily use is different in character from Arbaugh’s. He’s not playing video games for fun — though he does that too. He’s communicating with his family, attending his kids’ soccer games, speaking at his local church, and planning travel for the first time in five years. The Deseret News profiled him in May 2025, and the portrait is of a man who says “ALS still really sucks” while simultaneously describing the implant as a form of answered prayer. That combination of clear-eyed acknowledgment of the disease and genuine gratitude for what the device gives back is probably the most honest account of what these trials are producing for the people in them.

The VOICE trial, Neuralink’s follow-up program explicitly designed for speech restoration, enrolled its second participant — Kenneth Shock, another ALS patient — in January 2026. Musk confirmed in late March 2026 that the VOICE trial is producing results. 🗣️

The real-world friction nobody talks about

For all the remarkable capabilities, the honest accounting of Neuralink’s current state requires naming the things that don’t work yet or haven’t been solved. The MIT Technology Review analysis from January 2025 is still largely accurate in its framing: these are true experiments, not products.

Some unresolved realities as of early 2026:

• Thread retraction has happened and will probably happen again. The company has partial software mitigations, and the surgical robot is being refined to improve thread placement, but it’s not solved. Neuralink is targeting a “streamlined, almost entirely automated surgical procedure in 2026” that threads through the intact dura without removing it, which should reduce complications.

• Battery life at roughly five hours creates a rhythm of the day that able-bodied people never think about. You charge a phone when convenient. Charging a brain implant is more negotiated.

• Model drift means cursor control isn’t set-and-forget. The neural patterns the software reads shift over time, and recalibration is part of the regular routine. That’s not a dealbreaker, but it’s real work.

• Data security for a device that transmits neural signals wirelessly is a topic that gets almost no public discussion. Arbaugh’s X account was hacked and a false tip to local law enforcement sent a SWAT team to his home. These are separate events, but the collision of celebrity, vulnerability, and neural data creates risks that nobody has fully mapped yet.

What Neuralink is building in parallel is a surgical robot — already in use for implantation — that the company wants to eventually run with minimal human surgeon involvement. The goal is a procedure that looks less like brain surgery and more like an outpatient visit. Whether that’s achievable within the timelines Musk has publicly described is a genuinely open question. 💊

What the PRIME Study is actually producing

Beyond the individual stories, the aggregate data from PRIME is legitimately interesting. By February 2025, trial participants had collectively logged over 4,900 hours of device usage across more than 670 implant-days. That’s not cherry-picked demo footage — it’s sustained, daily, practical use by people for whom the alternative is profound isolation from the digital world.

The participants are scattered across four countries now. The most recent trial enrollment numbers put the PRIME Study at 21 participants, with the company aiming to expand toward larger enrollment as it pursues FDA Premarket Approval. The Blindsight implant — Neuralink’s visual cortex device — received an FDA Breakthrough Device Designation in June 2025, which doesn’t mean approval but does mean accelerated review.

What I find genuinely hard to resolve is the gap between those 21 participants and the scale of need. According to the Christopher and Dana Reeve Foundation, approximately 5.4 million Americans live with paralysis from various causes. ALS affects roughly 30,000 Americans at any given time. The PRIME Study is not a treatment rollout — it’s a controlled experiment to determine whether this can become one. The distance between 21 participants and clinical availability is measured in years and regulatory requirements that won’t bend for hype. 📈

The people in those trials know this. Arbaugh knew when he signed the consent forms that something could go terribly wrong. He said so publicly. “Even if it didn’t work — even if something went terribly wrong — I knew that it would help someone down the road.” That’s not the language of a true believer; it’s the language of someone who thought carefully about risk and decided the bet was worth making. The question worth sitting with isn’t whether the technology is impressive — it clearly is. It’s whether the systems being built around it, from surgical robots to signal security to regulatory frameworks, are advancing at the pace the technology demands.

So what should actually change in how this technology gets covered and discussed — and are there parts of the real patient experience that you think the industry is still not being honest about?

Now I have everything I need. Let me write this article.TITLE: The Brain Chip That Streams Thoughts in Real Time: What Columbia & Stanford Just Built SUBTITLE: A paper-thin silicon implant smaller than a fingernail just rewrote what brain-computer interfaces can do — and it may make the current state of the art look like dial-up.

Picture a chip the thickness of a human hair, roughly the size of your fingernail, sliding silently into the gap between your skull and your brain. No bulky canister. No tangle of wires threading through your cortex. Just a single wafer of silicon that listens to 65,536 electrodes simultaneously and fires neural data over a wireless link at 100 megabits per second — about 100 times faster than anything else currently on the market. That is the Biological Interface System to Cortex, better known as BISC, and it landed in Nature Electronics on December 8, 2025 with the kind of engineering ambition that tends to make the rest of the BCI field reconsider everything.

This is not a Neuralink press release, a Musk tweet, or a venture-funded demo. BISC came out of a research collaboration between Columbia University, Stanford University, NewYork-Presbyterian Hospital, and the University of Pennsylvania — funded by DARPA’s Neural Engineering System Design program — and its paper is dense with the kind of real electrophysiology data that neuroscientists actually care about. Senior author Ken Shepard, Lau Family Professor of Electrical Engineering at Columbia, led the chip engineering side. Senior author Andreas Tolias at Stanford anchored the neuroscience. The bridge between them produced something that looks less like a medical device and more like what the semiconductor industry does to room-sized computers when it decides they should fit in your pocket.

What BISC actually is

The quickest way to understand BISC is to start with what a typical brain implant looks like. Most current systems are built around a canister — a module stuffed with electronics that gets sealed into the skull or mounted on the chest, then connected to electrodes in the brain through a spaghetti of wires. The surgeries are long, the device is bulky, and the signal chain is lossy. Shepard describes the alternative bluntly: BISC slides into the subdural space — the thin gap between the outer membrane of the brain (the dura mater) and the cortical surface — “like a piece of wet tissue paper.”

Here’s what that chip actually packs in its 3 cubic millimeters:

• 65,536 titanium nitride electrodes arranged in a 256 × 256 grid

• 1,024 simultaneous recording channels, selectable from any position on the array

• 16,384 stimulation channels for sending signals back into the brain, not just reading out

• On-chip analog front-end, signal processing, analog-to-digital conversion, and a radio frequency transceiver — all on one CMOS substrate

• Wireless power via inductive link, so no battery sits inside the skull 🔋

The external piece is a wearable relay station, a headstage that beams power in and receives neural data out over a custom ultrawideband radio link. That link is the headline specification: 100 Mbps throughput, which the researchers confirm is at least 100 times higher than any competing wireless BCI currently available. The relay station then bridges to standard Wi-Fi, which means the brain, in a very literal sense, is on a network. 🌐

“Semiconductor technology has made this possible,” Shepard said in the Columbia press release, “allowing the computing power of room-sized computers to now fit in your pocket. We are now doing the same for medical implantables, allowing complex electronics to exist in the body while taking up almost no space.”

The engineering that actually makes it work

The honest answer to “why hasn’t anyone done this before?” is that merging electrodes and computation onto one substrate at this density is extremely hard. Most high-channel BCIs split the problem in two — electrodes here, processing there — and connect them with wires. That works, but the wire count scales badly, the connectors degrade, and you end up adding surgical complexity with every extra channel you want.

BISC’s breakthrough is monolithic integration 🔬: the electrodes and all supporting circuitry live on a single CMOS die, thinned to 50 micrometers. That last point matters enormously. At 50 μm, the chip is mechanically flexible — it can curve to follow the brain’s surface rather than pressing flat against it like a rigid board. The electrode pitch is approximately 28 micrometers, fine enough to capture retinotopic maps of the visual cortex at genuinely high resolution, which the team demonstrated in chronic recordings over multiple weeks.

A few technical details that deserve attention rather than burial:

• The analog-to-digital conversion and multiplexing happen on-chip, which is why you can stream 1,024 channels wirelessly without drowning the radio in raw analog noise

• The implant operates within strict thermal limits for subdural placement — the burst-based ultrawideband radio keeps power dissipation low enough that the chip doesn’t heat brain tissue

• Stimulation and recording can happen on the same device, which matters for closed-loop therapies where you read activity, process it, and respond with targeted electrical pulses in real time

• Chronic stability was verified across sessions spanning weeks in cortical recordings, with receptive fields shifting less than 0.05 degrees in eccentricity on average 📐

That chronic stability point is not academic. One of the persistent failure modes in BCI implants is signal degradation over time — electrodes scar, insulation breaks down, data quality slips. The fact that BISC maintains stable recordings over extended periods in animal models is what makes the human trial conversation even plausible.

Are you tracking what this means for the bandwidth problem that has hobbled BCI research for a decade? If you’re not, the short version is: more electrodes, read in parallel, transmitted wirelessly, with enough data throughput to run sophisticated AI decoders in real time. That combination has not existed in a subdural package before.

What this could actually treat

BISC’s clinical ambitions are specific, not vague. The paper and associated announcements identify five concrete conditions the system may address: 🏥

• Epilepsy — high-resolution cortical mapping for seizure prediction and targeted stimulation to interrupt seizure onset

• Spinal cord injury — decoding motor intention at sufficient bandwidth to drive prosthetic limbs or exoskeletons with the kind of nuance that current systems can’t capture

• ALS — speech restoration using the chip’s ability to decode intended speech from motor cortex activity before it reaches the throat

• Stroke — mapping perilesional activity and supporting neural rehabilitation through stimulation

• Blindness — encoding visual input into cortical stimulation patterns precise enough to restore useful vision

That last application is where Stanford’s neuroscience programs were particularly involved. The spatial resolution of 65,000 electrodes across the visual cortex opens up a different class of visual prosthetic than anything the Utah Array — the clinical workhorse since 2004, which typically offers a few hundred channels — could attempt. And BISC can stimulate as well as record, which is the fundamental requirement for writing visual information back into the brain. 👁️

The potential for ALS and paralysis applications builds on momentum already in the field. Stanford researchers separately demonstrated earlier this year that a BCI could decode unspoken sentences with up to 74% accuracy, using a device implanted in a person who had lost the ability to speak. BISC’s bandwidth and resolution should, in principle, push that accuracy considerably higher. “By combining ultra-high resolution neural recording with fully wireless operation,” Dr. Zeng said in the Columbia release, “and pairing that with advanced decoding and stimulation algorithms, we are moving toward a future” of restored function.

How BISC compares to Neuralink — and why the comparison is complicated

Neuralink is the name everyone knows, and that’s mostly because Elon Musk has a media presence that is itself a kind of neural implant for the news cycle. Neuralink’s Telepathy device, which has now been implanted in a small number of people with paralysis, uses penetrating electrodes — thin threads that go directly into the cortex, where neurons fire loudest and the signal quality is highest. The tradeoff is that “the brain doesn’t really like having needles put into it,” as Synchron founder Tom Oxley memorably put it in a 2022 TED talk.

BISC’s approach is different in a way that matters clinically. It sits on the surface of the brain, not inside it. This makes it less invasive than Neuralink in terms of tissue disruption, while still achieving dramatically more electrodes and bandwidth than previous surface-level devices. The honest comparison looks something like this:

• Neuralink: penetrating electrodes, higher single-neuron signal quality, ~1,000 channels, existing human data ⚡

• BISC: surface electrodes, 65,536 electrodes, 1,024 channels, 100 Mbps wireless, no human data yet

• Synchron (Stentrode): delivered through blood vessels, lowest invasiveness, lowest resolution

• Precision Neuroscience: surface arrays similar in philosophy to BISC, currently in early human trials

• Paradromics: highest raw channel count ambitions, penetrating, entering clinical trials late 2025

The Wikipedia overview of BCI approaches makes the core tension clear: invasiveness scales with signal quality, and every design is a bet on where that tradeoff should land. BISC bets that surface recording at extreme density, combined with powerful AI decoders, can match penetrating electrodes without the associated tissue damage. It’s a defensible position, though that claim needs human trial data before it’s settled science. 🧬

What nobody disputes is the bandwidth gap. 100 Mbps wireless throughput is genuinely unprecedented for an implantable BCI, and it opens up AI decoding architectures that are simply impossible on current systems — you can now feed a deep neural network the real-time activity of thousands of electrodes and let it find patterns that no human engineer designed the model to detect.

Kampto Neurotech and the road to a human skull

Research papers are great. Surgeries on actual people are the benchmark.

To move BISC from animal models to human patients, the Columbia and Stanford teams launched Kampto Neurotech, a startup founded by Columbia electrical engineering alumnus Dr. Nanyu Zeng, one of the project’s lead engineers. Kampto’s immediate focus is producing research-ready versions of the chip for preclinical work while simultaneously raising the capital needed to pursue a first-in-human trial. The company has already licensed the BISC technology from Columbia under US Patent 11617890 (issued April 4, 2023). 🚀

The path from here to a human trial is not trivial. BISC needs to clear FDA safety reviews, demonstrate long-term biocompatibility in chronic animal studies, and survive the kind of electromagnetic interference testing that tends to expose flaws in clever wireless designs. Those aren’t reasons to be dismissive — they’re the normal gauntlet that separates a promising chip from a clinical device. Neuralink went through years of that process before its 2024 first-in-human implant.

What Kampto has going for it is the institutional backing and engineering pedigree that some BCI startups lack. DARPA-funded research, three major academic medical centers, and a team that published the full architecture in a peer-reviewed Nature Electronics paper with a public GitHub repository for the data — that’s the kind of transparent science track record that the FDA and the investment community actually respond to. The chip’s performance has to hold up in humans, obviously, but the provenance here is legitimate.

What do you think the real bottleneck is — the engineering still left to do, the regulatory timeline, or the question of whether patients will actually consent to something this new? That’s probably where the most interesting debate in this space is happening right now, and it’s worth forming an opinion before the first human trial announcement turns the conversation into noise.

The headline sounds like something from a tech magazine circa 2040. “Control games with your mind.” And yet it’s May 2026, and you genuinely can do this. A pair of headphones with EEG sensors in the ear pads ships to your door for $499. A 19-year-old in Shanghai with a brain implant cleared the opening stages of Black Myth: Wukong using only his thoughts. Noland Arbaugh, who hasn’t been able to move his hands since a diving accident eight years ago, played Mario Kart with his father.

All of that is real. All of it happened recently. And if you’re excited by those three sentences, you should probably read a little further before you reach for your credit card — because “controlling a game with your mind” means something completely different depending on which technology you’re talking about, and most of the consumer-facing version is a lot more modest than the marketing implies. That’s not a reason to dismiss it. But it is a reason to understand what you’re actually buying.

What the consumer version actually does 🧠

Let’s start where most people will start: the devices you can actually buy without a surgeon. The most sophisticated consumer mind-control gaming product available right now is probably the Neurable MW75 Neuro, a collaboration between Neurable AI and Master & Dynamic. The original model costs $699. The newer MW75 Neuro LT, released in September 2025, trimmed about 12% of the weight and dropped to $499 — still not impulse-buy territory, but more realistic than the flagship.

These headphones look nearly identical to standard premium wireless headphones. The difference is in the ear pads: they contain 12 EEG channels made from soft fabric sensors that measure your brain’s electrical activity in real time. Neurable’s AI processes those signals and generates metrics — Focus Level, Calmness, Cognitive Speed, Anxiety Score — updated every second. The SoundGuys review describes the experience of seeing your focus spike as you concentrate on a task and flatten as your mind wanders. One reviewer wore the headset while playing a side-scrolling shooter on a Steam Deck and watched the data trace their learning curve in the first level, then settle as the controls became automatic.

This is real. It’s not pseudoscience, and it’s not fake. Neurable validated the technology in a study with 132 participants, and they’ve done follow-on work with the Mayo Clinic. The headset really does capture meaningful neural signals from an otherwise normal-looking pair of headphones.

Here’s the catch: what it does with those signals is not direct game control. Not yet. The MW75 Neuro tracks your cognitive state — how focused you are, when you’re approaching mental fatigue — and uses that data to suggest brain breaks, show you productivity patterns, and give you a window into how your brain performs through the day. The gaming application is more about self-awareness than mind control. You wear the headset while gaming and see the neural data alongside your session. You don’t move characters with your thoughts.

What consumer EEG gaming actually looks like in 2026:

• Passive cognitive monitoring during gameplay — tracking attention states, alertness, and focus as overlays or companion app data

• Simple binary control in purpose-built applications — games designed specifically for BCI input, where you “push” with concentration or “pull” with relaxation, a bit like pressing a single button with your brain

• Adaptive game environments that adjust difficulty based on your measured mental load — easier when you’re fatigued, harder when you’re locked in

• Neurofeedback games where the explicit goal is to practice brain control, training attention regulation rather than playing traditional games

That’s meaningful. That’s actually a category of experience that didn’t exist five years ago. But if you’re imagining yourself steering a car through a Mario Kart track purely by thinking “left” and “right,” you’re picturing something the consumer hardware can’t deliver today. 💡

What the implant version actually feels like ⚡

For the full version — the one where you’re playing a complex video game with your thoughts at something approaching normal speed and accuracy — you need an implant. That’s the honest answer, and I think it’s important to say it plainly rather than let the consumer marketing blur the line.

Noland Arbaugh became the first person to receive Neuralink’s “Telepathy” N1 chip in January 2024. The device sits in his skull, sealed, with ultra-thin electrode threads woven into his motor cortex. Within a month, he was controlling a cursor on his laptop screen by imagining moving a cursor. Then came chess. Then Mario Kart with his father watching. As Arbaugh told Neuralink’s company meeting: “I am so blessed to be part of it. It’s only been a month and I can’t believe how much my life has changed.”

Arbaugh described the experience as imagining moving his hand, even though his hand doesn’t move. The signal that would have driven hand movement is intercepted by the chip before it reaches his paralyzed muscles, decoded by software, and translated into cursor position on screen. It’s not reading thoughts exactly — it’s reading motor intent. The distinction matters, because it means the training process is largely about learning to produce consistent motor imagery, which most people can do once they understand what the system is looking for.

In April 2025, a different story emerged from Shanghai. BrainXBot — a collaboration involving the Tianqiao Brain Science Research Institute and the Shanghai Institute of Microsystems — reported that a 19-year-old epilepsy patient played complex games after receiving their Beinao-1 implant. According to Tom’s Hardware’s reporting, the training process took roughly 20 hours — about three times faster than Arbaugh’s initial Neuralink training — and the patient achieved 4.07 bits per second of cursor control performance, approaching the 4.6 bits per second Arbaugh achieved after 60 hours. He played Black Myth: Wukong and Honor of Kings and also controlled a smart wheelchair and home devices using the same system.

The patient’s pathway to gaming:

• Started with basic titles like Pac-Man and Tank Wars to build motor imagery consistency

• Graduated to cursor-based internet navigation, app control, and smart home commands

• Reached complex action games after approximately 20 hours of brain training

• Achieved cursor response speed “approaching the level of normal people using a mouse,” according to the company

The physical sensation of using an implanted BCI is something no reviewer has described in the way you’d describe holding a controller. Arbaugh said it felt natural quickly — that imagining movement became an almost unconscious process after a while, the way you stop thinking about which fingers press which keys when you type. That’s the version of mind-controlled gaming that feels like the science fiction. It’s also the version that currently requires open-skull surgery. 🔬

The gap — and why it’s not as simple as “wait for better technology” 📈

Consumer EEG and implanted BCI aren’t really on the same innovation timeline heading toward the same destination. They’re different tools for different things, and understanding that is more useful than assuming one will eventually become the other.

The limitations of non-invasive EEG for high-fidelity game control are physics problems, not just engineering problems. Your skull scatters electrical signals badly. The sensor sits centimeters from the neurons generating the signal, separated by bone, fluid, and tissue. The result is blurry, low-resolution data compared to what you get from an electrode touching the cortex directly. A 2024 study flagged what researchers call “BCI illiteracy“ — the finding that roughly 20% of potential users simply cannot generate the kind of consistent, distinguishable brain signals that consumer EEG needs to decode intent reliably. That’s not a fixable user error. For some people’s neural architecture, EEG control of complex inputs may never work well.

That’s a specific limitation worth naming. A technology that doesn’t work for one in five people isn’t ready to be everyone’s controller. The honest framing from neuroscientists is that consumer EEG gaming today is best thought of as a layer of information on top of traditional input rather than a replacement for it. You play the game normally; the EEG data enriches the experience or adapts the environment.

Implanted BCIs face a different set of constraints:

• Surgical requirement limits the addressable population to people for whom the medical benefit clearly outweighs the risk

• Regulatory pathways mean every new application (gaming, communication, vision, emotion) needs its own clinical evidence

• Device longevity is still being established — how long do these implants remain functional and safe? Years of data are still being collected

• Electrode drift can degrade signal quality over time as tissue gradually reacts to the implant

I find the discourse around this frustrating because it tends to collapse into either “mind control gaming is almost here” hype or “this is dangerous sci-fi” dismissal, when the actual picture is more nuanced. The technology is real and working, it helps real people meaningfully, and the path to mainstream gaming applications involves solving problems that range from practical engineering to regulatory philosophy. That’s worth sitting with rather than skipping past. 💡

Where the hardware is actually heading 🚀

The most instructive recent data point isn’t from Neuralink or BrainXBot. It’s a January 2025 paper in Nature Medicine from a Stanford University team led by researchers working with a participant who has tetraplegia. They developed a finger-based BCI that allows continuous control of three independent finger groups, with the thumb controllable in two dimensions — totaling four degrees of freedom from thought alone. The system achieved an average acquisition rate of 76 targets per minute, with completion times under two seconds. The same system controlled a quadcopter game.

Four degrees of freedom. Seventy-six targets per minute. Those numbers matter because they’re approaching the precision needed for real game control, not just cursor movement. The game controller in your hands has more degrees of freedom than that, but not infinitely more — and the gap is closing faster than most people realize.

The consumer gaming market is moving in parallel. The BCI gaming market was valued at $144 million in 2024 and is projected to reach $927 million by 2034 at a 20.5% annual growth rate, per Polaris Market Research. That trajectory reflects genuine commercial interest, not just optimism. Game developers are starting to design with BCI inputs in mind. The integration of focus-tracking APIs into engines like Unity is already happening at the indie level.

What I think the next three years actually look like, based on the data:

• Consumer EEG gets genuinely useful as a gaming companion layer — adaptive difficulty, burnout prevention, focus-state overlays — without ever becoming a primary controller for most games

• Hybrid inputs start appearing: a controller you hold, augmented by brain signals that add a fifth or sixth axis of subtle control, like changing camera sensitivity based on your attention state

• Clinical BCI gaming expands meaningfully as more patients receive implants through Neuralink, Synchron, and BrainXBot’s growing trial programs

• New form factors for non-invasive devices — Merge Labs’ ultrasound approach, if it works, could eventually offer signal quality between today’s EEG and implants, without surgery

As we’ve tracked in our coverage of the signals that neurotech is approaching its tipping point, the field is accelerating. And as we’ve written about the consumer neurotech devices you can actually buy today, some of that technology is already in your living room — it just doesn’t look the way you’d expect.

The version where a healthy person sits down, puts on a light headset, and plays a complex game using only their thoughts — with no degraded controls, no calibration ritual, no 20% failure rate — that version is probably still years away for non-invasive devices. The version where someone with paralysis uses a brain implant to reclaim control of games and their digital life? That’s happening now, quietly, in clinical trial sites in the United States, Australia, and China.

So the question worth asking yourself isn’t “when will mind-controlled gaming be real?” It already is. The real question is: which problem matters more to you, the performance ceiling of consumer devices or the access barrier of clinical ones — and which of those do you think gets solved first? 👇

Somewhere in a server farm right now, a file containing your brain activity probably exists. Maybe you wore an EEG headband to improve your sleep. Maybe you tried a meditation device that promised to measure your focus. Maybe you played around with one of the consumer neurofeedback products that have been popping up in electronics stores like particularly ambitious Fitbits. Whatever the entry point, if you’ve used a consumer neurotech device in the last few years, there’s a reasonable chance your neural data left your skull and landed somewhere you never thought about.

This isn’t fearmongering. It’s the finding of a systematic, 100-page investigation. In April 2024, the Neurorights Foundation, a Columbia University-affiliated nonprofit led by neuroscientist Rafael Yuste, analyzed the privacy policies and user agreements of 30 consumer neurotechnology companies. The numbers were stark: 29 out of 30 companies effectively claimed ownership over every piece of neural data collected through their devices. 20 out of 30 explicitly reserved the right to share or sell that data to third parties. Only one company had any meaningful restrictions. Yuste’s word for the user agreements: “predatory.”

The conversation about what’s happening to your financial data, your location data, your health data — all of it — has been happening loudly for years. The conversation about your brain data has barely started. That’s the gap this piece is trying to close.

What neural data actually is, and why it’s different from everything else 🧠

When people hear “brain data,” they imagine a neuroscientist in a lab coat watching a glowing scan of your skull while you think about your mother. The reality is both more mundane and more alarming. Neural data is any information generated by measuring the electrical, chemical, or vascular activity of your nervous system — and it doesn’t require surgery or a hospital to collect.

Consumer EEG headbands record voltage fluctuations across your scalp. Meditation apps process those signals into emotional state estimates. Sleep trackers identify sleep stages from brain wave patterns. Even some wellness earbuds with embedded sensors now log what your auditory cortex is doing while you commute. The collection is happening quietly, continuously, and in contexts that feel nothing like a medical procedure.

California’s SB 1223, which took effect on January 1, 2025, offers the clearest legal definition of what counts: information “generated by measuring the activity of a consumer’s central or peripheral nervous system, and that is not inferred from non-neural information.” The Future of Privacy Forum calls this “the broadest conception” adopted by any U.S. state so far, because it includes signals from the peripheral nervous system (think EMG data from muscles) in addition to brain activity. 🔬

Here’s what makes neural data categorically different from other sensitive data types:

• It can identify you even when anonymized. Research cited by TechPolicy Press shows that brain patterns can be cross-referenced with social media photos to re-identify individuals, even when data has been stripped of names and metadata

• It reveals information you haven’t disclosed. Neural signals can expose mental health conditions, emotional states, cognitive patterns, and political inclinations — none of which you agreed to share

• It’s far richer than necessary. A Neurorights Foundation analysis found that consumer devices often collect roughly 10,000 times more data than the application actually uses, leaving companies with vast stores of raw neural signal they have no stated purpose for

• It cannot be reset. Your password can be changed. Your credit card can be reissued. Your brain activity pattern is yours forever, which means a breach is permanent

I think this last point doesn’t get nearly enough attention. Every data breach risk framework I’ve ever seen treats data loss as a recoverable event. For neural data, there’s no recovery. Once your EEG fingerprint is out, it’s out.

The fine print problem 🔬

It’s worth pausing on what those 30 privacy policies actually said — or didn’t say. The Neurorights Foundation’s report found that fewer than half of the companies surveyed even encrypt the neural data they collect, let alone de-identify it. Most policies were written in language vague enough to permit almost any downstream use. And, critically, most of them said nothing at all about data broker relationships.

Here’s the uncomfortable legal reality that Senators Chuck Schumer, Maria Cantwell, and Ed Markey spelled out in a 2025 letter to the FTC: devices classified as “wellness” products don’t fall under HIPAA. Neuralink, because it’s a medical device, has to comply with federal health data protection law. But the meditation headband you bought on Amazon? Under current federal law, the company can do almost whatever it wants with the signals your neurons generated. The “wellness” label is doing a lot of regulatory heavy lifting, and not in your favor.

What companies are actually doing with collected neural data varies, but the range of disclosed uses in those 30 policies included:

• Sharing with “business partners” and “affiliates” — terms broad enough to include advertisers

• Training AI models on aggregated neural datasets, with no clear limits on what those models learn about emotional or cognitive patterns

• Transferring data in the event of a “merger, acquisition, or sale of assets” — meaning your brain data is a transferable business asset

• “Research purposes” with no definition of what research, by whom, or with what oversight

The phrase that keeps appearing in these policies is some variation of “as described in this policy” — which describes almost nothing. A group of researchers at Neuroethics Canada put it bluntly: the risks are compounded by “the behavior of consumers who accept user agreements with little regard to their terms, thereby giving access to their brain data for mining, analytics, and purchase by third parties.” Which is to say: the system is working exactly as designed, and the design is not in your favor. Is this actually surprising to you, or does it feel inevitable? 💡

The law is scrambling, unevenly ⚡

The regulatory picture in 2026 is a patchwork of state laws, stalled federal proposals, and international guidelines that carry no enforcement power. The short version: some protection exists in a few U.S. states, almost none exists at the federal level, and the European framework is clearer in theory than in practice.

Colorado moved first, signing the world’s first neural data protection bill into law in April 2024 — extending the Colorado Privacy Act to cover consumer neurotech devices. California’s SB 1223 followed, effective January 2025. Montana and Connecticut (with SB 1295, signed June 2025) completed the initial group of four states with neural data law on the books.

As of early 2026, a Morrison Foerster analysis cited by Inside BCI identified active neural data bills in Virginia, Alabama, New York, Illinois, and Vermont — each taking a different approach:

• Virginia HB 654 folds neural data into the existing definition of biometric data under state privacy law

• Alabama HB 263 creates a standalone neural data statute, which is a stronger structural choice because it can’t be quietly diluted by biometric data carve-outs

• Illinois HB 5179 gives individuals a private right of action — if a company unlawfully transfers your neural data to a third party, you’re presumed to have suffered at least $10,000 in damages, without having to prove actual harm

• New York’s S9008 would treat neural data under data broker regulations, which is an interesting angle given how much data broker infrastructure already exists

The federal picture is more discouraging. Senators Schumer, Cantwell, and Markey introduced the MIND Act (S.B. 2925) in September 2025, which would direct the FTC to conduct a one-year study of neural data practices and recommend national standards. As of May 2026, the bill hasn’t moved out of committee. Directing an agency to study something is already a pretty mild intervention; failing to even pass that is a sign of how little political momentum this issue currently has.

Internationally, the EU’s GDPR almost certainly covers neural data under its “special categories” rules for biometric and health data, but there are no neuro-specific provisions. The OECD published neurotechnology governance principles in 2019. UNESCO has a draft ethics instrument under intergovernmental negotiation since 2024. In 2025, the UN Special Rapporteur on privacy urged all states to enact targeted protections. None of this is binding. France and Germany are separately drafting employment-specific laws to prohibit mandatory neurotech adoption in workplace contracts, which is at least a concrete step toward a specific risk.

The most consequential legal ruling so far came from Chile’s Supreme Court, which became the world’s first court to protect brain data under a constitutional neurorights provision. That’s genuinely remarkable. It’s also a single ruling in one country, and it required a constitutional amendment first.

Why the stakes just got higher 🧬

The case for urgency didn’t need more evidence, but 2025 delivered some anyway. In August 2025, researchers at Stanford University published results showing that an AI system translated neural signals from a woman with ALS — referred to only as participant T16 — into readable sentences in real time. The work was presented as a speech restoration breakthrough, and it is one. It’s also a proof of concept for something more unsettling: if AI can reconstruct intended speech from neural signals, the technical barrier between “brain data collection” and “thought reading” is now a matter of engineering, not science.

Japanese researchers reported a parallel advance shortly after, demonstrating “mind captioning” — generating detailed descriptions of images a person was seeing or imagining, using non-invasive brain scans combined with multiple AI systems. The accuracy wasn’t perfect. It doesn’t need to be perfect to be dangerous.

What this means for the current state of neural data privacy:

• The data being collected now may be far more decodable in five years than it is today. Companies that acquire it under current “wellness” terms will have it when the decoding tools are ready

• Re-identification will get easier. As AI models trained on neural data improve, the “anonymized” datasets sitting in company servers become progressively less anonymous

• Research cited in a 2024 Neuron paper by Farahany and Ienca found that AI can infer political ideology from brain scan data — a fact that has specific implications when neural data ends up with data brokers in politically sensitive contexts

• The workplace dimension is already arriving. Pilot programs in 2025 explored cognitive monitoring for drivers, air traffic controllers, and office workers. A peer-reviewed analysis published in EMBO Reports in 2025 flagged the potential for neural data to appear in criminal proceedings, raising urgent self-incrimination concerns

The argument that gets made most often in response to all of this is: “Well, the data is low-resolution. Consumer EEGs aren’t capturing your actual thoughts.” That’s true right now. It’s a comfort that has a shorter shelf life than most people realize.

What you can actually do today 📈

I’m not going to pretend that individual action is a substitute for systemic regulation. It isn’t. But while the regulators catch up, a few things are actually within your control.

Before buying or using any consumer neurotech device:

• Read the privacy policy before purchasing. Specifically look for: what data is collected; whether it’s sold to third parties; how long it’s retained; and what happens to your data if the company is acquired. If the policy doesn’t address those questions, that absence is itself an answer

• Check your state protections. If you’re in California, Colorado, Connecticut, or Montana, you have legal rights around neural data that you may not know about — including the right to request deletion

• Prefer companies with explicit data minimization commitments. Some companies do commit in writing to collecting only what’s necessary for the stated function. Those commitments aren’t legally watertight everywhere, but they’re better than nothing and they create an accountability record

• Be skeptical of “wellness” framing. Products that position themselves as wellness rather than medical devices are deliberately outside HIPAA’s scope. That’s a choice companies make with regulatory consequences in mind

If you’re a developer, engineer, or founder building in this space, the 7 competitive advantages piece on NeurotechMag makes a point worth internalizing: data trust is a moat. Companies that build real privacy protections in now — not as compliance theater, but as architecture — will look dramatically different from their peers when the regulatory environment tightens. And it will tighten.

As we noted in our coverage of consumer neurotech devices you can buy today, “there’s a bigger conversation emerging about regulation and ethics — because once you start collecting neural data, questions about privacy, consent, and data use matter. Very much.” That conversation is overdue. The question is whether enough people demand it before the data already collected becomes impossible to claw back.

So here’s what I’d actually like to know: if your neurotech device’s privacy policy said explicitly that your brain signals could be sold to a data broker — would you still use it? And if the answer is no, why haven’t you checked whether that’s already happening? 👇